Valuation of Asbestos-Related Disease Liabilities of former James Hardie entities ("the Liable Entities") to be met by the AICF Trust

Prepared for Asbestos Injuries Compensation Fund Limited ("AICFL")

As at 31 March 2018

22 May 2018
22 May 2018

Narreda Grimley
General Manager
Asbestos Injuries Compensation Fund Limited
Suite 1, Level 6, 56 Clarence Street
Sydney NSW 2000

Cc Matthew Marsh, Chief Financial Officer, James Hardie Industries plc
Karen Smith, Deputy Secretary, Legal, Department of Premier and Cabinet, The State of New South Wales
The Board of Directors, Asbestos Injuries Compensation Fund Limited

Dear Narreda

Valuation of Asbestos-Related Disease Liabilities of former James Hardie entities ("The Liable Entities") to be met by the AICF Trust

We are pleased to provide you with our Annual Actuarial Report relating to the asbestos-related disease liabilities of the Liable Entities which are to be met by the AICF Trust.

The report is effective as at 31 March 2018 and has taken into account claims data and information provided to us by AICFL as at 31 March 2018.

If you have any questions with respect to the contents of this report, please do not hesitate to contact us.

Yours sincerely

Neil Donlevy MA FIA FIAA
Executive, KPMG Financial Services Consulting Pty Ltd
Fellow of the Institute of Actuaries (London)
Fellow of the Institute of Actuaries of Australia

Jefferson Gibbs BSc FIA FIAA
Executive, KPMG Financial Services Consulting Pty Ltd
Fellow of the Institute of Actuaries (London)
Fellow of the Institute of Actuaries of Australia

© 2018 KPMG Financial Services Consulting Pty Ltd is a member firm of the KPMG network of independent member firms affiliated with KPMG International Cooperative ("KPMG International"), a Swiss entity. All rights reserved. The KPMG name, logo and "cutting through complexity" are registered trademarks of KPMG International. Liability limited by a scheme approved under Professional Standards Legislation.
Executive Summary

Important Note: Basis of Report

This valuation report (“the Report”) has been prepared by KPMG Actuarial, a division of KPMG Financial Services Consulting Pty Ltd (ABN 91 144 686 046) (hereafter collectively referred to as “KPMG” or “KPMG Actuarial”) in accordance with an “Amended and Restated Final Funding Agreement in respect of the provision of long-term funding for compensation arrangements for certain victims of Asbestos-related diseases in Australia” (hereafter referred to as the “the Amended Final Funding Agreement”) between James Hardie Industries NV (now known as James Hardie Industries plc) (hereafter referred to as “James Hardie”), James Hardie 117 Pty Limited, the State of New South Wales and Asbestos Injuries Compensation Fund Limited (“AICFL”) which was signed on 21 November 2006.

This Report is intended to meet the requirements of the Amended Final Funding Agreement and values the asbestos-related disease liabilities of the Liable Entities to be met by the AICF Trust.

This Report is not intended to be used for any other purpose and may not be suitable, and should not be used, for any other purpose. Opinions and estimates contained in the Report constitute our judgment as of the date of the Report.

The information contained in this Report is of a general nature and is not intended to address the objectives, financial situation or needs of any particular individual or entity. It is provided for information purposes only and does not constitute, nor should it be regarded in any manner whatsoever as, advice and is not intended to influence a person in making a decision in relation to any financial product or an interest in a financial product. No one should act on the information contained in this Report without obtaining appropriate professional advice after a thorough examination of the accuracy and appropriateness of the information contained in this Report having regard to their objectives, financial situation and needs.

In preparing the Report, KPMG has relied on information supplied to it from various sources and has assumed that the information is accurate and complete in all material respects. KPMG has not independently verified the accuracy or completeness of the data and information used for this Report.

Except insofar as liability under statute cannot be excluded, KPMG, its executives, directors, employees and agents will not be held liable for any loss or damage of any kind arising as a consequence of any use of the Report or purported reliance on the Report including any errors in, or omissions from, the valuation models.

The Report must be read in its entirety. Individual sections of the Report, including the Executive Summary, could be misleading if considered in isolation. In particular, the opinions expressed in the Report are based on a number of assumptions and qualifications which are set out in the full Report.
Introduction

The Amended Final Funding Agreement requires the completion of an Annual Actuarial Report evaluating the potential asbestos-related disease liabilities of the Liable Entities to be met by the AICF Trust. KPMG has been retained by AICFL to provide this Annual Actuarial Report as required under the Amended Final Funding Agreement and this is detailed in our Engagement Letter dated 16 November 2017.

The Liable Entities are defined as being the following entities:

- Amaca Pty Ltd (formerly James Hardie & Coy);
- Amaba Pty Ltd (formerly Jsekarb, James Hardie Brakes and Better Brakes); and
- ABN60 Pty Ltd (formerly James Hardie Industries Ltd).

In addition, the liability for Baryulgil claims is deemed to be a liability of Amaca by virtue of the James Hardie (Civil Liability) Act 2005 (NSW). Under Part 4 of that Act, Amaca is liable for the “Marlew Asbestos Claims” or “Marlew Contribution Claims” as defined in that Act.

Our valuation is on a central estimate basis and is intended to be effective as at 31 March 2018. It has been based on claims data and information as at 31 March 2018 provided to us by AICFL.

Overview of Recent Claims Experience and comparison with previous valuation projections

In this section we compare the actual experience in 2017/18 (referred to in the following tables as “FY18 Actual”) with the projections for 2017/18 that were contained within our previous valuation report at 31 March 2017. We will refer to these projections for 2017/18 as “FY18 Expected” in the tables that follow.

Claim numbers

There have been 392 mesothelioma claims reported in 2017/18, a 5% increase compared to the 374 mesothelioma claims reported in 2016/17 and 5% above expectations for 2017/18 (372 claims).

For non-mesothelioma claims (excluding workers compensation claims), there have been 150 claims reported in 2017/18, a 6% decrease compared to 159 claims reported in 2016/17.

The following table shows the comparison of actual experience with that which had been forecast at the previous valuation.
Average Claim Awards

Average claims awards in 2017/18 have been lower than expectations across all disease types with the exception of workers compensation.

There has been one large mesothelioma claim settlement (being claims in excess of $1m in 2006/07 money terms) in 2017/18. This is significantly lower than our expectations. Total claims expenditure on large claims has been 85% below expectations, reflecting the low number of large claims reported and settled in 2017/18.

The following table shows the comparison of actual experience with that which had been forecast at the previous valuation.

**Table E.1. Comparison of claim numbers**

<table>
<thead>
<tr>
<th>Disease Type</th>
<th>FY18 Actual</th>
<th>FY18 Expected</th>
<th>Ratio of Actual to Expected (%)</th>
<th>FY17 Actual</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mesothelioma</td>
<td>392</td>
<td>372</td>
<td>105%</td>
<td>374</td>
</tr>
<tr>
<td>Asbestosis</td>
<td>85</td>
<td>108</td>
<td>79%</td>
<td>97</td>
</tr>
<tr>
<td>Lung Cancer</td>
<td>26</td>
<td>21</td>
<td>124%</td>
<td>19</td>
</tr>
<tr>
<td>ARPD &amp; Other</td>
<td>31</td>
<td>33</td>
<td>94%</td>
<td>32</td>
</tr>
<tr>
<td>Wharf</td>
<td>8</td>
<td>12</td>
<td>67%</td>
<td>11</td>
</tr>
<tr>
<td>Workers</td>
<td>20</td>
<td>30</td>
<td>67%</td>
<td>24</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>562</strong></td>
<td><strong>576</strong></td>
<td><strong>98%</strong></td>
<td><strong>557</strong></td>
</tr>
</tbody>
</table>

**Note:** FY17 Actuals have been inflated (by 4%) to mid 2017/18 values

**Table E.2. Comparison of average claim size of non-nil claims**

<table>
<thead>
<tr>
<th>Disease Type</th>
<th>FY18 Actual ($)</th>
<th>FY18 Expected ($)</th>
<th>Ratio of Actual to Expected (%)</th>
<th>FY17 Actual ($)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mesothelioma</td>
<td>300,491</td>
<td>364,000</td>
<td>83%</td>
<td>286,271</td>
</tr>
<tr>
<td>Asbestosis</td>
<td>104,786</td>
<td>118,200</td>
<td>89%</td>
<td>81,625</td>
</tr>
<tr>
<td>Lung Cancer</td>
<td>117,067</td>
<td>131,900</td>
<td>89%</td>
<td>42,336</td>
</tr>
<tr>
<td>ARPD &amp; Other</td>
<td>66,285</td>
<td>105,500</td>
<td>63%</td>
<td>75,972</td>
</tr>
<tr>
<td>Wharf</td>
<td>78,668</td>
<td>116,100</td>
<td>68%</td>
<td>38,373</td>
</tr>
<tr>
<td>Workers</td>
<td>241,667</td>
<td>137,200</td>
<td>176%</td>
<td>0</td>
</tr>
<tr>
<td>Mesothelioma Large Claims (settled)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number</td>
<td>1</td>
<td>5.6</td>
<td>18%</td>
<td>2</td>
</tr>
<tr>
<td>Average claim size</td>
<td>2,000,000</td>
<td>2,331,600</td>
<td>86%</td>
<td>1,703,000</td>
</tr>
<tr>
<td>Large claim expenditure</td>
<td>2,000,000</td>
<td>13,056,960</td>
<td>15%</td>
<td>3,406,000</td>
</tr>
</tbody>
</table>

**Note:** FY17 Actuals have been inflated (by 4%) to mid 2017/18 values
Cashflow expenditure: gross and net

Gross cashflow expenditure, at $139.7m, was 10% below expectations.

Net cashflow expenditure, at $123.7m, was 16% below expectations.

Table E.3. Comparison of cashflow

<table>
<thead>
<tr>
<th></th>
<th>FY18 Actual ($)</th>
<th>FY18 Expected ($)</th>
<th>Ratio of Actual to Expected (%)</th>
<th>FY17 Actual ($)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gross Cashflow</td>
<td>139.7</td>
<td>154.9</td>
<td>90%</td>
<td>125.0</td>
</tr>
<tr>
<td>Insurance and Other</td>
<td>(11.4)</td>
<td>(8.2)</td>
<td>139%</td>
<td>(22.3)</td>
</tr>
<tr>
<td>Recoveries</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Insurance recoveries</td>
<td>(4.6)</td>
<td>0.0</td>
<td>n/a</td>
<td>(105.0)</td>
</tr>
<tr>
<td>from HIH and from</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>commutations</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Net Cashflow</td>
<td>123.7</td>
<td>146.7</td>
<td>84%</td>
<td>(2.3)</td>
</tr>
</tbody>
</table>

Gross cashflow was lower than expectations primarily due to the lower average claim size of non-large mesothelioma claims together with lower expenditure on large mesothelioma claims, partially offset by higher numbers of mesothelioma claims settlements in 2017/18.

Liability Assessment

At 31 March 2018, our projected central estimate of the liabilities of the Liable Entities (the Discounted Central Estimate) to be met by the AICF Trust is $1,852.9m (March 2017: $1,740.1m). We have not allowed for the future Operating Expenses of the AICF Trust or the Liable Entities in the liability assessment.

Table E.4. Comparison of central estimate of liabilities

<table>
<thead>
<tr>
<th></th>
<th>31 March 2018 $m</th>
<th>31 March 2017 $m</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Gross of insurance recoveries</td>
<td>Insurance recoveries</td>
</tr>
<tr>
<td>Total uninflated and</td>
<td>1,517.3</td>
<td>74.4</td>
</tr>
<tr>
<td>undiscounted cash-flows</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inflation allowance</td>
<td>972.7</td>
<td>34.7</td>
</tr>
<tr>
<td>Total inflated and</td>
<td>2,490.0</td>
<td>109.1</td>
</tr>
<tr>
<td>undiscounted cash-flows</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Discounting allowance</td>
<td>(551.8)</td>
<td>(23.7)</td>
</tr>
<tr>
<td>Net present value</td>
<td>1,938.2</td>
<td>85.4</td>
</tr>
<tr>
<td>liabilities</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Comparison with previous valuation

In the absence of any change to the claim projection assumptions from our 31 March 2017 valuation, other than allowing for the changes in the discount rate, we would have projected a Discounted Central Estimate liability of $1,657.1m as at 31 March 2018.

This is a decrease of $83.0m relative to the valuation result at 31 March 2017, and this is due to:

- A reduction of $119.9m, being the net impact of expected claims payments (which reduce the liability) and the “unwind of discount” (to reflect the fact that cashflows are now one year nearer).
- An increase of $36.9m resulting from changes to the yield curve between 31 March 2017 and 31 March 2018.

Our liability assessment at 31 March 2018 of $1,852.9m represents an increase of $195.8m, which arises from changes to the actuarial assumptions. The increase is principally a consequence of:

- The revised modelling approach for mesothelioma which has allowed for higher numbers of claims after 2025 partially offset by reductions in average sizes by allowing for the impact of claimant age; and
- An increase to the base level of mesothelioma claims for 2018/19 and the consequential impact this has on the number of claims in all future years;

offset by

- Removal of the allowance for *Sullivan vs Gordon* in Victoria (see Section 1.3.3 of this Report);
- Increased allowance for cross-claim recoveries; and
- Reductions for average claim sizes and defence legal costs for other disease types.

The following chart shows an analysis of the change in our liability assessments from 31 March 2017 to 31 March 2018 on a discounted basis.

**Figure E.1. Analysis of change in central estimate liability (discounted basis)**

![Chart showing analysis of change in central estimate liability](chart.png)

*Note: Green bars signal that this factor has given rise to an increase in the liability whilst light blue bars signal that this factor has given rise to a reduction in the liability.*
Amended Final Funding Agreement calculations

The Amended Final Funding Agreement sets out the basis on which payments will be made to the AICF Trust.

Additionally, there are a number of other figures specified within the Amended Final Funding Agreement that we are required to calculate. These are:

- Discounted Central Estimate;
- Term Central Estimate; and
- Period Actuarial Estimate.

Table E.5. Amended Final Funding Agreement calculations

<table>
<thead>
<tr>
<th>Description</th>
<th>$m</th>
</tr>
</thead>
<tbody>
<tr>
<td>Discounted Central Estimate (net of cross-claim recoveries,</td>
<td>1,852.9</td>
</tr>
<tr>
<td>Insurance and Other Recoveries)</td>
<td></td>
</tr>
<tr>
<td>Period Actuarial Estimate (net of cross-claim recoveries,</td>
<td>462.7</td>
</tr>
<tr>
<td>gross of Insurance and Other Recoveries) comprising:</td>
<td></td>
</tr>
<tr>
<td>Discounted value of cashflow in 2018/19</td>
<td>147.1</td>
</tr>
<tr>
<td>Discounted value of cashflow in 2019/20</td>
<td>159.4</td>
</tr>
<tr>
<td>Discounted value of cashflow in 2020/21</td>
<td>156.2</td>
</tr>
<tr>
<td>Term Central Estimate (net of cross-claim recoveries,</td>
<td>1,835.5</td>
</tr>
<tr>
<td>Insurance and Other Recoveries)</td>
<td></td>
</tr>
</tbody>
</table>

The actual funding amount due at a particular date will depend upon a number of factors, including:

- the net asset position of the AICF Trust at that time;
- the free cash flow amount of the James Hardie Group in the preceding financial year; and
- the Period Actuarial Estimate in the latest Annual Actuarial Report.

Uncertainty

Estimates of asbestos-related disease liabilities are subject to considerable uncertainty, significantly more than personal injury liabilities in relation to other causes, such as CTP or Workers Compensation claims.

It should therefore be expected that the actual emergence of the liabilities will vary from any estimate. As indicated in Figure E.2, depending on the actual out-turn of experience relative to that currently forecast, the variation could potentially be substantial.

Thus, no assurance can be given that the actual liabilities of the Liable Entities to be met by the AICF Trust will not ultimately exceed the estimates contained in this Report. Any such variation may be significant.

We have performed sensitivity testing to identify the impact of different assumptions upon the size of the liabilities. The different scenarios selected are documented at Section 11.2 of this report.
We have not included a sensitivity test for the impact of changes in discount rates although, as noted in this Report, changes in discount rates can introduce significant volatility to the Discounted Central Estimate result reported at each year-end.

We note that these sensitivity test ranges are not intended to correspond to a specified probability of sufficiency, nor are they intended to indicate an upper bound or a lower bound of all possible outcomes.

Figure E.2. Sensitivity testing results – Impact around the Discounted Central Estimate (in $m)

The single most sensitive assumption shown in the chart is the peak period of claims reporting against the Liable Entities. Shifting the pattern of incidence by 2 years could add approximately $325m (18%) on a discounted basis to our valuation (as shown in the above chart by the scenario labelled “mesothelioma incidence pattern”).

Table E.6. Summary results of sensitivity analysis ($m)

<table>
<thead>
<tr>
<th></th>
<th>Undiscounted</th>
<th>Discounted</th>
</tr>
</thead>
<tbody>
<tr>
<td>Central estimate</td>
<td>2,380.9</td>
<td>1,852.9</td>
</tr>
<tr>
<td>Low Scenario</td>
<td>1,681.3</td>
<td>1,347.2</td>
</tr>
<tr>
<td>High Scenario</td>
<td>4,209.8</td>
<td>3,062.0</td>
</tr>
</tbody>
</table>

Whilst the table above indicates a range around the discounted central estimate of liabilities of -$506m to +$1,209m, the actual cost of liabilities could fall outside that range depending on the actual experience.

Executive Summary Not Report

Please note that this executive summary is intended as a brief overview of our Report. To properly understand our analysis and the basis of our liability assessment requires examination of our Report in full.
Contents

Executive Summary iii
1. Scope and Purpose 1
2. Data 10
3. Valuation Methodology and Approach 13
4. Claims Experience: Mesothelioma Claim Numbers 27
5. Claims Experience: Claim numbers (non-mesothelioma) 37
6. Exposure and Latency Experience and Incidence Pattern Assumptions 40
7. Claims Experience: Average Claims and Legal Costs 49
8. Claims Experience: Nil Settlement Rates 63
9. Economic and Other Assumptions 70
10. Valuation Results 77
11. Uncertainty 85

Appendices

A Projected inflated and undiscounted cashflows ($m) 89
B Projected inflated and discounted cashflows ($m) 90
C Australian asbestos consumption and production data: 1930-2002 91
D Glossary of terms used in the Amended Final Funding Agreement 92
1. **Scope and Purpose**

1.1 **Introduction**

The Amended Final Funding Agreement requires the completion of an Annual Actuarial Report evaluating the potential asbestos-related disease liabilities of the Liable Entities to be met by the AICF Trust.

1.1.1 **Liable Entities**

The Liable Entities are defined as being the following entities:

- Amaca Pty Ltd (formerly James Hardie & Coy);
- Amaba Pty Ltd (formerly Jsekarb, James Hardie Brakes and Better Brakes); and
- ABN60 Pty Ltd (formerly James Hardie Industries Ltd).

In addition, the liability for Baryulgil claims is deemed to be a liability of Amaca by virtue of the James Hardie (Civil Liability) Act 2005 (NSW). Under Part 4 of that Act, Amaca is liable for “Marlew Asbestos Claims” or “Marlew Contribution Claims” as defined in that Act.

1.1.2 **Personal asbestos claims**

Under the Amended Final Funding Agreement, the liabilities to be met by the AICF Trust relate to personal asbestos-related disease liabilities of the Liable Entities.

Such claims must relate to exposure which took place in Australia and which have been brought in a Court in Australia.

The precise scope of the liabilities is documented in Section 1.2 and in Appendix D of this Report.

1.1.3 **Purpose of report**

KPMG has been retained by AICFL to provide an Annual Actuarial Report as required under the Amended Final Funding Agreement and this is detailed in our Engagement Letter dated 16 November 2017.

The prior written consent of KPMG is required for any other use of this Report or the information contained in it.

Our valuation is effective as at 31 March 2018 and has been based on claims data and information as at 31 March 2018 provided to us by AICFL.
1.2 Scope of report

We have been requested to provide an actuarial assessment as at 31 March 2018 of the asbestos-related disease liabilities of the Liable Entities to be met by the AICF Trust, consistent with the terms of the Amended Final Funding Agreement.

The assessment is on a central estimate basis and is based on the claims experience as at 31 March 2018.

A “central estimate” liability assessment is an estimate of the expected value of the range of potential future liability outcomes. In other words, if all the possible values of the liabilities are expressed as a statistical distribution, the central estimate is an estimate of the mean of that distribution.

It is of note that our liability assessment:

- Relates to the Liable Entities and Marlew (in relation to Marlew Claims arising from asbestos mining activities at Baryulgil).

- Is intended to cover:
  - The amount of settlements, judgments or awards for all Personal Asbestos Claims.
  - Claims Legal Costs incurred by the AICF Trust in connection with the settlement of Personal Asbestos Claims.

- Is not intended to cover:
  - Personal injury or death claims arising from exposure to asbestos which took place outside Australia.
  - Personal injury or death claims, arising from exposure to Asbestos, which are brought in Courts outside Australia.
  - Claims for economic loss, other than any economic loss forming part of an award for damages for personal injury and/or death.
  - Claims for loss of property, including those relating to land remediation.
  - The costs of asbestos or asbestos product removal relating to asbestos or asbestos products manufactured or used by or on behalf of the Liable Entities.

- Includes an allowance for:
  - Compensation to the NSW Dust Diseases Board or a Workers Compensation Scheme by way of a claim by such parties for contribution or reimbursement from the Liable Entities, but only to the extent that the cost of such claims is within the limits of funding for such claims as outlined within the Amended Final Funding Agreement.
  - Workers Compensation claims, being claims from former employees of the Liable Entities, but only to the extent that such liabilities are not met by a Workers Compensation Scheme or Policy (see section 1.2.1).

- Assumes that the product and public liability insurance policies of the Liable Entities will continue to respond to claims as and when they fall due. We have not made any
allowance for the impact of any disputation concerning Insurance Recoveries, nor for any legal costs that may be incurred in resolving such disputes.

- Makes no allowance for:
  - Insurance Recoveries from insurance policies placed from 1986 onwards which were placed on a “claims made” basis.
  - the future Operating Expenses of the Liable Entities or the AICF Trust. Separate allowance for future Operating Expenses should be considered by the management of AICFL.
  - the inherent uncertainty of the liability assessment. That is, no additional provision (or risk margin) has been included in excess of a central estimate.

Readers of this Report may refer to our previous reports which are available at www.ir.jameshardie.com.au and www.aicf.org.au.

1.2.1 Workers Compensation

Workers Compensation claims are claims made by former employees of the Liable Entities. Such past, current and future reported claims were insured with, amongst others, Allianz Australia Limited, QBE and the various State-based Workers Compensation Schemes.

Under the Amended Final Funding Agreement, the part of a future Workers Compensation claim that is met by a Workers Compensation Scheme or Policy of the Liable Entities is outside of the AICF Trust. The AICF Trust is, however, to provide for any part of a claim not covered by a Workers Compensation Scheme or Policy (e.g. as a result of the existence of limits of indemnity and policy deductibles on those policies of insurance).

On this basis our liability assessment in relation to Workers Compensation claims and which relates to the AICF Trust, includes only the amount borne by the Liable Entities in excess of the anticipated recoveries due from a Workers Compensation Scheme or Policy.

In making our assessment we have assumed that the Workers Compensation insurance programme will continue to respond to claims by former employees of the Liable Entities as and when they fall due. To the extent that they were not to respond owing to (say) insurer insolvency, Insurer Guarantee Funds may be available to meet such obligations.

1.2.2 Dust Disease Board and Other Reimbursements

There exists a right under Section 8E (Reimbursement Provisions) of the Dust Diseases Act 1942 for the NSW Dust Diseases Board (“DDB”) to recover certain costs from common law defendants, excluding the employer of the claimant.

This component of cost is implicitly included within our liability assessment as the claims awards made in recent periods and in recent settlements contain allowance for DDB reimbursement where applicable. Furthermore, currently reported open claims have an allowance within their case estimates for the costs of DDB reimbursement where relevant and applicable.

The Amended Final Funding Agreement indicates that the AICF Trust is intended to meet Personal Asbestos Claims and that claims by the DDB or a Workers Compensation Scheme
for reimbursement will only be met up to a certain specified limit (aggregated across the DDB and Workers Compensation Schemes), being:

- In the first financial year (2006/07) a limit of $750,000 applied;
- In respect of each financial year thereafter, that limit is indexed annually in line with the Consumer Price Index. At 31 March 2018, the annual limit is $985,738;
- There is an overall unindexed aggregate cap of $30m;
- At 31 March 2018, AICFL has paid out $9,495,875 to the DDB. Additionally, there are approximately $2.7m of unpaid claims at 31 March 2018; the pace of payment of which would be subject to the impact of the annual limit.

The cashflow and liability figures contained within this Report have already removed that component of any reimbursements that will not be met by the AICF Trust owing to the application of these limits and caps.

### 1.2.3 Baryulgil ("Marlew Claims")

"Marlew Asbestos Claims" and "Marlew Contribution Claims" are deemed to be liabilities of Amaca. These claims specifically include:

- Claims made against Amaca Pty Ltd or ABN60 resulting from their past ownership of the mine; and, in the case of Amaca, includes claims made in relation to the joint venture (Asbestos Mines Pty Ltd) established with Wunderlich in 1944 to begin mining at Baryulgil.
- Claims made against the subsequent owner of the mine (following its sale by James Hardie Industries to Woodsreef in 1976), being Marlew Mining Pty Ltd ("Marlew") which is in liquidation, are to be met by the AICF Trust except where such claims are Excluded Marlew Claims, which are recoverable by the Claimant from other sources.

These claims are discussed further in Section 5.8.

### 1.2.4 Risk Margins

Australian-licensed insurance companies are required to hold, and many non-insurance companies elect to hold, insurance and self-insurance claims provisions at a level above the central estimate basis to reflect the uncertainty attaching to the liability assessment and to include an allowance in respect of that uncertainty.

A risk margin is an additional amount held, above the central estimate, so as to increase the likelihood of adequacy of the provisions to meet the ultimate cost of settlement of those liabilities.

We note that the Amended Final Funding Agreement envisages the ongoing financing of the AICF Trust is to be based on a “central estimate” approach and that the Annual Actuarial Report should provide a Discounted Central Estimate valuation.

Accordingly, we have made no allowance for any risk margins within this Report.
1.2.5 Discounting

We have determined a Discounted Central Estimate in this Report by discounting (to 31 March 2018) the projected future cashflows using yields on Commonwealth Government Bonds.

Conceptually, the Discounted Central Estimate at 31 March 2018 would normally represent an amount of money which, if fully provided in advance (i.e. as of 31 March 2018) and invested in risk-free assets (such as Commonwealth Government Bonds) of term and currency appropriate to the liabilities, would generate the necessary investment income such that (together with the capital value of those assets) it would be expected to be sufficient to pay for the liabilities as they fall due.

To the extent that the actual investments are:

- of different terms; and/or
- in different currencies; and/or
- provide different expected rates of return

investment profits or losses would emerge.

One of the uncertainties in our valuation is the fact that fixed interest Commonwealth Government Bonds do not exist at most of the durations of our cashflow projection.

This means we need to take a long-term view on bond yields that is not measured by market-observable rates of return.

We note that the actual funding mechanism under the Amended Final Funding Agreement only provides for up to three years’ worth of projected Claims and Claims Legal Costs expenditure and one year’s worth of Operating Expenses at any one time.

1.3 Areas of potential exposure

As identified in Section 1.2, there are other potential sources of claims exposure beyond those directly considered within this Report. However, in a number of cases they are unquantifiable even if they have the potential to generate claims. This is especially the case for those sources of future claim where there has been no evidence of claims to date.

1.3.1 General areas of potential exposure

Areas of potential changes in claims exposure we have not explicitly allowed for in our valuation include, but are not limited to:

- Future significant individual landmark and precedent-setting judicial decisions;
- Significant medical advancements;
- Unimpaired claims, i.e. claims for fear, stress, pure nervous shock or psychological illness;
- A change in the basis of compensation for asymptomatic pleural plaques for which no associated physical impairment is exhibited;
- A proliferation (compared to past and current levels of activity) of “third-wave” claims, i.e. claims arising as a result of indirect exposure such as home renovation, washing
clothes of family members that worked with asbestos, or from workers involved in the removal of asbestos or the demolition of buildings containing asbestos;

- Changes in legislation, especially those relating to tort reform for asbestos sufferers. Examples include the current consultation by the Law Reform Commission in Western Australia in relation to damages for gratuitous services and provisional damages;
- Introduction of new, or elimination of existing, heads of damage;
- Exemplary and aggravated or punitive damages (being damages awarded for personal injuries caused as a result of negligence or reckless conduct);
- Changes in the basis of apportionment of awards for asbestos-related diseases for claimants who have smoked (we note the decisions in Amaca v Ellis [2010] HCA 5 and Evans v Queanbeyan City Council [2010] NSWDDT 7 which we understand are consistent with the previous decision in Judd v Amaca [2002] NSWDDT 25);
- Changes to taxation; and
- Future bankruptcies of other asbestos claim defendants (i.e. other liable manufacturers or distributors).

Nonetheless, implicit allowance is made in respect of some of these items in the allowance for superimposed inflation included in our liability assessment. Furthermore, to the extent that some of these have emerged in past claims experience, they are reflected in our projections.

1.3.2 New Zealand and other overseas exposures

We have made no allowance for the risk of further development in relation to New Zealand exposures and the rights of claims from New Zealand claimants in Australian courts (as per Frost v Amaca (2005), NSWDDT 36 although this decision was successfully appealed by Amaca in August 2006) nor for the risk of additional exposures from overseas.

This is because, as noted in Section 1.2, the AICF Trust is not required to meet the cost of these claims as they are Excluded Claims.

In relation to claimants where exposures have involved more than one country (e.g. UK and Australia), we have assumed that the AICF Trust will only meet that part of the cost which is attributable to the Australian-related exposure.

1.3.3 Victorian amendments to the Wrongs Act

In 2015, the State of Victoria implemented amendments to the Wrongs Act (the Wrongs Amendment Act 2015) to incorporate the payment of Sullivan vs Gordon awards (or more formally, Section 281D). These amendments came into force on 19 November 2015.

The Department of Justice and Regulation of Victoria made amendments to the Regulations that apply to Dust Diseases, namely the Wrongs (Part VB) (Dust and Tobacco-Related Claims) Regulations 2006.

The effect of the various amendments is that from 10 May 2016, the AICF Trust was required to pay for Sullivan vs Gordon awards (to the extent applicable) in relation to claims brought against the Liable Entities in Victoria.
Our liability assessment at 31 March 2017 therefore included an allowance for these as they were Payable Liabilities under the Amended Final Funding Agreement.

Our valuation at 31 March 2017 included the following amounts:

- $56.8m on an uninflated & undiscounted basis.
- $94.2m on an inflated & undiscounted basis.
- $73.2m on an inflated & discounted basis.

A Deed of Amendment to the Amended Final Funding Agreement was made on 19 December 2017 to insert a new clause (13.4A). The effect of these amendments is that *Sullivan vs Gordon* awards (Section 281D damages) cannot be paid by AICF and the Liable Entities with effect from 1 January 2018.

Accordingly, our valuation at 31 March 2018 has removed the allowance previously made within our 31 March 2017 valuation for these awards.

1.3.4 Third-wave claims

We have made allowance for so-called “third-wave” claims. These are defined as claims for personal injury and / or death arising from asbestos exposure during home renovations by individuals or to builders involved in such renovations. Such claims are allowed for within the projections to the extent to which they have arisen to date and to the extent our exposure model factors in these exposures in its projection.

We have not allowed for a significant additional surge in third-wave claims (over and above current levels of activity) in the future arising from renovations, but conversely we have not allowed for a tempering of those third-wave claims already included within our projection as a result of improved education of individuals as to the risks of such home renovations, or of any local Councils or State Governments passing laws in this regard.

It should be noted that claims for the cost of asbestos or asbestos product removal from homes and properties or any claims for economic loss arising from asbestos or asbestos products being within such homes and properties is not required to be met by the AICF Trust.

1.4 Data reliances and limitations

KPMG has relied upon the accuracy and completeness of the data with which it has been provided. KPMG has not verified the accuracy or completeness of the data, although we have undertaken steps to test its consistency with data previously received. However, KPMG has placed reliance on the data previously received, and currently provided, as being accurate and complete in all material respects.

1.5 Uncertainty

It must be understood that estimates of asbestos-related disease liabilities are subject to considerable uncertainty.

This is due to the fact that the ultimate disposition of future claims will be subject to the outcome of events that have not yet occurred. Examples of these events, as noted in Section 1.3, include jury decisions, court interpretations, legislative changes, epidemiological
developments, medical advancements, public attitudes, potential additional third-wave exposures and social and economic conditions such as inflation.

Therefore, it should be expected that the actual emergence of the liabilities will vary, perhaps materially, from any estimate. Thus, no assurance can be given that the actual liabilities of the Liable Entities to be met by the AICF Trust will not ultimately exceed the estimates contained herein. Any such variation may be significant.

1.6 Distribution and use

The purpose of this Report is as stated in Section 1.1.

This Report should not be used for any purpose other than those specified.

This Report will be provided to the Board and management of AICFL. This Report will also be provided to the Board and management of James Hardie, the NSW Government and to EY in their capacity as auditors to both James Hardie and AICFL.

We understand that this Report will be filed with the ASX and placed on James Hardie’s website in its entirety.

We understand that this Report will also be placed on AICFL’s website in its entirety.

KPMG consents to this Report being made available to the above-mentioned parties and for the Report to be distributed in the manner described above.

To the extent permitted by law, neither KPMG nor its Executives, directors or employees will be responsible to any third parties for the consequences of any actions they take based upon the opinions expressed with this Report, including any use of or purported reliance upon this Report not contemplated in Section 1.2. Any reliance placed is that party’s sole responsibility.

Where distribution of this Report is permitted by KPMG, the Report may only be distributed in its entirety and judgements about the conclusions and comments drawn from this Report should only be made after considering the Report in its entirety and with necessary consultation with KPMG.

Readers are also advised to refer to the “Important Note: Basis of Report” section at the front of the Executive Summary of this Report.

1.7 Date labelling convention used in this Report

In our analyses throughout this Report (unless otherwise stated), the “year” we refer to aligns with the financial year of AICFL and James Hardie and runs from 1 April to 31 March.

A “2008” notified claim would be a claim notified in the period 1 April 2008 to 31 March 2009. This might also be referred to as “2008/09” or “FY09”.

Similarly, a “2017” claim settlement would be a claim settled in the period 1 April 2017 to 31 March 2018. This might also be referred to as “2017/18” or “FY18”.
1.8 Author of the report

This Report is authored by Neil Donlevy, an Executive of KPMG Financial Services Consulting Pty Ltd, a Fellow of the Institute of Actuaries (London) and a Fellow of the Institute of Actuaries of Australia.

This Report is co-authored by Jefferson Gibbs, an Executive of KPMG Financial Services Consulting Pty Ltd, a Fellow of the Institute of Actuaries (London) and a Fellow of the Institute of Actuaries of Australia.

In relation to this Report, the primary regulator for both Neil Donlevy and Jefferson Gibbs is the Institute of Actuaries of Australia.

1.9 Professional standards and compliance

This Report details a valuation of the outstanding claims liabilities of entities which hold liabilities with features similar to general insurance liabilities.

In preparing this Report, we have complied with the Professional Standard 300 of the Institute of Actuaries of Australia ("PS300"), "Valuation of General Insurance Claims".

However, as we note in Section 1.2, this Report does not include an allowance for the future Operating Expenses of the AICF Trust (which are estimated by AICFL) and nor does it include any allowance for a risk margin to reflect the inherent uncertainty in the liability assessment.

1.10 Control processes and review

This valuation report and the underlying analyses have been subject to technical review and internal peer review.

The technical review focuses on ensuring that the valuation models and supporting claims experience analyses that are carried out are performed correctly and that the calculations are being correctly applied. The technical review also focuses on ensuring that the data that is being used has been reconciled insofar as possible.

Internal peer review involves a review of the approach, the methods, the assumptions selected and the professional judgments applied.

Both the technical review and internal peer review processes are applied to the Report as well as the valuation models.

1.11 Basis of preparation of Report

We have been advised by the management of AICFL to prepare the Report on a “going concern” basis (i.e. we should assume that AICFL will be able to meet any shortfall in the cost of the liabilities of the Liable Entities as they fall due).

The cashflow estimates contained in this Report assume that claims against the Liable Entities will continue to be paid in full as and when they fall due.
2. Data

2.1 Data provided to KPMG

We have been provided with the following data by AICFL:

- Claims dataset at 31 March 2018 with individual claims listings;
- Accounting transactions dataset at 31 March 2018 (which includes individual claims payment details); and
- Detailed insurance bordereaux information (being a listing of claims filed with the insurers of the Liable Entities) as at 31 March 2018.

We have allowed for the benefits of the product and public liability insurance policies of the Liable Entities based on information provided to us by AICFL relating to the insurance programme’s structure, coverage and layers.

We have also considered the claims data listings which formed the basis of our previous valuation assessments. The data structures provided for the claims and accounting datasets are consistent with those provided at previous valuations.

2.2 Data limitations

We have tested the consistency of the various data sets provided to us at different valuation dates. Section 2.3 outlines the nature of the testing undertaken.

However, we have not otherwise verified the data and have instead relied on the data provided as being complete and accurate in all material respects.

We have relied upon the robustness of AICFL’s internal administration and systems as to the completeness of the data provided.

Consequently, should there be material errors or incompleteness in the data, our assessment could also be affected materially.

2.3 Data reconciliation and testing

We have performed a reconciliation of the data provided at 31 March 2018 with the data provided at 31 March 2017.

We have undertaken a number of tests and reconciliations to test the accuracy of the data to the extent possible, noting the limitations outlined above.
2.3.1 Reconciliation with previous valuation’s data

We have performed a reconciliation of the claims database as at 31 March 2018 with that provided at 31 March 2017.

Our findings are:

- Claims notifications: There were no new claims reported that had a report date prior to 31 March 2017. No claims (that already had a notification date) changed notification date between the two databases.

- Portfolio category: Seven claims changed category. Five of these related to claims reported in 2016/17.

- Settlement date: There have been two claims with a settlement date prior to 31 March 2017 that changed settlement dates.

Changing and developing data is not unexpected or to be considered as adverse. Indeed, changing data is common to all claims administration systems. We do not consider the number or extent of the changes noted above to be unreasonable, nor do we consider the changes to be material to the valuation.

2.3.2 Reconciliation of claims settlement amounts between claims and accounting databases

We have mapped the financial data between the claims and accounting databases into standardised groupings as follows:

Table 2.1: Grouping of financial data from claims and accounting databases

<table>
<thead>
<tr>
<th>CLAIMS DATABASE</th>
<th>ACCOUNTING DATABASE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Award</td>
<td>Damages (gross of cross-claims) plus DDB reimbursement plus Medicare (from Accounting Database)</td>
</tr>
<tr>
<td>Costs</td>
<td>Costs plus Other less Medicare (from accounting database)</td>
</tr>
<tr>
<td>Defence legal costs</td>
<td>Defence legal costs</td>
</tr>
</tbody>
</table>

Note: Recovery amounts are available from the accounting database

We have compared the payment records between the claims database and the accounting database from the earliest date to the current file position.

The table below shows the results of this reconciliation for all claim transactions to date.

Table 2.2: Comparison of amounts from claims and accounting databases ($m)

<table>
<thead>
<tr>
<th>CLAIMS DATABASE</th>
<th>ACCOUNTING DATABASE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Damages (gross of recoveries, excluding medicare)</td>
<td>1,605.9</td>
</tr>
<tr>
<td>Costs</td>
<td>47.4</td>
</tr>
<tr>
<td>DDB</td>
<td>14.6</td>
</tr>
<tr>
<td>Other (inc Medicare)</td>
<td>5.4</td>
</tr>
<tr>
<td>Defence legal costs</td>
<td>184.8</td>
</tr>
<tr>
<td>Total Value</td>
<td>1,858.0</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Standardisation</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Award plus Medicare plus DDB</td>
<td>1,623.7</td>
</tr>
<tr>
<td>Costs / Other</td>
<td>49.5</td>
</tr>
<tr>
<td>Defence legal costs</td>
<td>184.8</td>
</tr>
<tr>
<td>Total Value</td>
<td>1,858.0</td>
</tr>
</tbody>
</table>
The standardisation is the most relevant comparison because the two database extracts allocate the information (particularly in relation to Medicare) in slightly different ways.

Once the standardisation has been undertaken, the two datasets reconcile closely – with reconciliation differences for claim awards totalling approximately $2.6m or 0.2% (31 March 2017: $10.3m). The reduction in the difference in the past 12 months reflects work undertaken by AICFL during 2017/18 to further enhance the quality and consistency of the various data sources.

Our approach for each claim record has been to take the maximum value of the two databases for each claim record. This results in the following overall totals being used in our analysis:

- $1,627.0m for the claims award component;
- $50.5m for the costs / other component; and
- $185.6m for the defence legal costs component.

This approach, of taking the maximum value for each claims record, may result in some minor prudence in our overall analysis although the amount of prudence is not considered to be significant in the context of the size of the potential liabilities and the underlying uncertainty in any valuation estimating future claims costs over the next 40 years or more.

### 2.4 Data conclusion

We have not verified the underlying data nor have we undertaken “auditing at source”. No material data issues have been identified and notified to us by the Approved Auditor of AICFL (EY) during their testing.

We have tested the data for internal consistency with the data provided at the previous valuation (31 March 2017).

Based on that testing and reconciliation, and subject to the limitations described in Section 1.4, we have formed the view that:

- Generally, the data is consistent between valuations, with any differences in the data being readily explainable;
- The financial data appears to reconcile reasonably between the two data sources (the claims dataset and the accounting transactions datasets);
- Any data issues that have emerged are not significant in relation to the size of the liabilities; and
- The data is appropriate for use for the purpose of this Report.
3. Valuation Methodology and Approach

3.1 Valuation methodology changes

We have, in broad terms, maintained the core valuation methodology adopted at our previous valuation.

The key methodology change at this valuation is that we have sub-divided the mesothelioma segment into four age groups, based on the age of the claimant at the time the claim was notified.

These age groups are:

- Under 60 years of age;
- 60 to 70 years of age;
- 70 to 80 years of age; and
- 80 years of age or over.

We have sub-divided the mesothelioma segment into these age groups to reflect the fact that the mix of claims has changed materially over time.

We have observed that average claim sizes of non-nil, non-large claims; the incidence rate of large claims; and the latency of mesothelioma claims varies between each of these age groups.

By modelling these age groups separately and deriving separate assumptions for each age group, it allows us to respond more directly to the change in mix of claims that has occurred over time and which is projected to continue to occur in future periods.

As a consequence of the change in approach, there are changes to the overall future pattern of incidence, and projected future number, of mesothelioma claims being assumed as well as changes in average claim sizes assumed in future periods.

We have not changed the methodology in relation to the other disease types and for those disease types we have continued to adopt the incidence patterns that were assumed in our 31 March 2017 valuation.
3.2 Overview of current methodology

The methodology involves assessing the liabilities in two separate components, being:

- Allowance for the cost of settling claims which have already been reported but have not yet been settled ("pending claims"); and
- Allowance for the cost of settling claims which have not yet been reported ("Incurred But Not Reported" or "IBNR" claims).

For pending claims, we have used the case estimates (where available) with some adjustments to reflect the extent to which the case estimates (on average) tend to overstate the ultimate cost. For IBNR claims we have used what can best be described as an “average cost per claim method”.

In brief, the overall methodology may be summarised as follows:

- Project the future number of claims expected to be reported in each future year by disease type (for product and public liability) and for Workers Compensation and wharf claims taking into account the expected future incidence of mesothelioma and other diseases and also the past rate of co-joining of the Liable Entities;
- Analyse past average attritional claim costs of non-nil claims in mid 2017/18 money terms. We have defined attritional claims to be claims which are less than $1m in 2006/07 money terms. We estimate a baseline attritional non-nil average claim cost in mid 2017/18 money terms. This represents the Liable Entities’ share of a claim rather than the total claim settlement;
- Analyse past historical average plaintiff/other and defendant legal costs for non-nil claim settlements;
- Analyse past historical average defendant legal costs for nil claim settlements;
- Estimate a “large claims loading” for mesothelioma claims by estimating the frequency, or incidence rate, and average claim size and legal cost sizes of such claims (being claims which are in excess of $1m in 2006/07 money terms);
- Project the pattern and incidence of future claims settlements from the claims reporting profile projected. This is done by using a settlement pattern derived from consideration of past experience of the pattern of delay between claim reporting and claim settlement for each disease type;
- Estimate the proportion of claims which will be settled with no liability against the Liable Entities by reference to past proportions of claims settled for nil claim cost (we refer to this as the “nil settlement rate”);
- Inflate average claim, plaintiff/other and defence legal costs and large claim costs to the date of settlement of claims allowing for base inflation and (where applicable) superimposed inflation;
- Multiply the claims numbers which are expected to be settled for non-nil amounts in a period by the inflated average non-nil claim costs (including the “large claims loading”) and plaintiff/other and defence legal costs for that period;
- Make allowance in defence legal costs for that proportion of settled claims which are expected to be settled for no liability but for which defence costs will be incurred;
- Inflate average defence legal costs of nil claims to the date of settlement of claims allowing for base inflation;
- Multiply the claims numbers which are expected to be settled for nil amounts in a period by the inflated average defence legal costs for nil claims for that period;
- Add the expected claims costs and legal payments relating to pending claims (after allowance for the potential savings on case estimates) after making allowance for the assumed settlement pattern of pending claims;
- This gives the projected future gross cashflow for each future financial year;
- Adjust the projected gross cashflow for the impact of the annual and aggregate caps on DDB reimbursements;
- Estimate the recoveries resulting from cross-claims made by the Liable Entities against other parties (“cross-claim recoveries”);
- Project Insurance Recoveries to establish the net cashflows;
- Discount the cashflows using a yield curve derived from yields on Commonwealth Government Fixed Interest Bonds at the valuation date to arrive at our present value liability assessment.

It should be noted that this description is an outline and is not intended to be exhaustive in consideration of all the stages we consider or all investigations we undertake. Those other stages are outlined in more detail elsewhere in this Report and readers are advised to refer to those sections for a more detailed understanding of the process undertaken.

As discussed elsewhere, the liabilities are established on a central estimate basis.
3.3 Disease type and class subdivision

3.3.1 Claims records excluded from our analysis

We have excluded records that relate to cross-claims brought by the Liable Entities against other defendants. Where the cross-claim is brought as part of the main proceedings the claim is automatically counted in our analysis of the number of claims. However, where the cross-claim by the Liable Entities is severed from the main proceedings, the existence of a separate record in the claims dataset does not indicate an additional claim (or liability) against the Liable Entities. In these circumstances such claims records are not counted in our analysis.

We have also excluded “insurance recovery” claims records. This is because the insurance recovery record is a separate record that exists for claims records where an insurance recovery is due. In other words, the claim against the Liable Entity has already been included in our analysis and the insurance recovery record exists for operational purposes only.

3.3.2 Categories of claim

We have sub-divided the remaining claims into the following groups:

- Product and Public Liability;
- Workers Compensation, being claims by former employees of the Liable Entities; and
- Wharf claims, being claims by individuals whose occupations involved working on the docks or wharves, or where part of their exposure related to wharves.

3.3.3 Categories of disease

For product and public liability claims, we have separately analysed the individual disease types.

We have split the data by disease type for these claims, because there is sufficient volume of claims to do so, because different disease types display substantially different average claim sizes, and because the incidence pattern of future notifications is expected to vary between the different disease types.

We have not divided the Workers Compensation or wharf claims data by disease type, given their low financial significance and the reduced credibility of the data if sub-divided by disease type (given the low number of claims).

For the purposes of our analysis, we have allocated each claim once and therefore to one disease only. We have selected the following order of priority, based on the relative severity of the disease:

- Mesothelioma;
- Lung cancer / Other cancer;
- Asbestosis; and then
- Asbestos-Related Pleural Disease and Other (“ARPD & Other”).

This means that if a product or public liability claim has mesothelioma as one of its listed diseases, it is counted as a mesothelioma claim. If a product or public liability claim has lung
cancer or other cancer as one of its listed diseases (but not mesothelioma), it is counted as a lung cancer claim. If a product or public liability claim has asbestosis as one of its listed diseases, it is only counted as asbestosis if it has no reference to mesothelioma, lung cancer or other cancer as one of its diseases.

3.4 Numbers of future claims notifications: mesothelioma

To project the pattern of incidence of claims against the Liable Entities, we have constructed a revised model which utilises the following inputs:

- The current Australian population by year of birth / current age and gender;
- Standard mortality rates by age and gender. This is used to project the population by year of birth / age at each future year;
- The relative risk-exposure (or incidence rates) between males and females;
- The relative risk-exposure by age of person at time of exposure;
- The exposure to asbestos in Australia;
- The statistical distribution of the latency period from average exposure for each disease type and by age of claimant, together with the underlying parameters (the mean and the standard deviation) of the latency model.

3.4.1 Population data

The chart below shows the current population of Australia by year of birth and split between males and females. The most recent data was effective as at December 2016.

Figure 3.1: Australian population at December 2016

Source: Australian Bureau of Statistics
3.4.2 Mortality rates by age

We have used mortality rates from Australian Life Tables 2010-2012 which show mortality rates separately by age and gender.

Figure 3.2: Mortality rates: Australia Life Tables 2010-2012

3.4.3 Risk-weighting adjustment: males to females

Data available from numerous literature indicates that the incidence of mesothelioma is significantly higher for males than females. Data from the Australian Mesothelioma Registry, for example, shows the following table.

Table 3.1: Number of people in Australia diagnosed with mesothelioma: 2011 to 2016

<table>
<thead>
<tr>
<th>Year</th>
<th>Male</th>
<th>Female</th>
<th>Male: Female ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>2011</td>
<td>595</td>
<td>106</td>
<td>18%</td>
</tr>
<tr>
<td>2012</td>
<td>609</td>
<td>126</td>
<td>21%</td>
</tr>
<tr>
<td>2013</td>
<td>574</td>
<td>131</td>
<td>23%</td>
</tr>
<tr>
<td>2014</td>
<td>614</td>
<td>142</td>
<td>23%</td>
</tr>
<tr>
<td>2015</td>
<td>554</td>
<td>156</td>
<td>28%</td>
</tr>
<tr>
<td>2016</td>
<td>559</td>
<td>141</td>
<td>25%</td>
</tr>
<tr>
<td>Total</td>
<td>3,505</td>
<td>802</td>
<td>23%</td>
</tr>
</tbody>
</table>

Source: Mesothelioma in Australia 2016: 6th Annual Report, prepared by the Australian Mesothelioma Registry

The same report also notes that for 2016, age-standardised incidence rates were 4.2 per 100,000 males and 0.9 per 100,000 females.

We have therefore, when using the population as a proxy for incidence/exposure, applied a 25% factor to the female population statistics to reflect the lower rate of incidence of mesothelioma for females relative to males. This means that 80% of claims arise from males (for the same number of males and females within a population).
3.4.4 Risk-weighting adjustment: age of person at time of exposure

The following analysis shows how the relative risk of exposure reflects the age at the time of exposure. This is used to adjust the exposure measure (see Section 3.4.5) based on the age of the person at the time of potential exposure.

The chart has aggregated all years of exposure and all years of claim and is based on the claims and exposure data provided by AICFL.

Figure 3.3: Exposure (in exposure person-years) by age at time of exposure

The chart shows that most of the claims have emerged from exposure between the ages of 20 and 50. The absence of exposure at older ages reflects the fact that exposure at older ages do not tend to manifest in claims owing to natural mortality from other factors before the possibility of emergence of the disease, given the latency is typically around 35 to 40 years.

In particular, it can be observed that (in broad terms):

- 3% of the exposure has arisen under the age of 15 years.
- 8% of the exposure has arisen between the ages of 15 and 19.
- 76% of the exposure has arisen between the ages of 20 and 49.
- 10% of the exposure has arisen between the ages of 50 and 59.
- 3% of the exposure has arisen at ages 60 or older.

3.4.5 Exposure model

We have constructed a proxy for exposure by reference to statistics showing the levels of Australian usage of asbestos. We do not have detailed individual exposure information for the Liable Entities, its products or where the products were used and how many people were exposed to those products.

However, given the market share of James Hardie over the years (through to 1987) and its relative stability, we have used a national pattern of usage as a reasonable proxy for the Liable Entities’ exposure.
3.4.6 Latency model

Our assumption is that the latency pattern (from the average date of exposure) is statistically distributed with a normal distribution.

The parameters for the mean (40 years) and for the standard deviation (9 years) of the latency period have been set taking into account the claims experience of the Liable Entities to date and epidemiological studies.

The analysis supporting the selection of these parameters is summarised in Section 6.1.

3.4.7 Calibrating the curve index to current reporting experience

We take the claim curve index and then calibrate the number of notifications in each future year by reference to the recent levels of claims reporting and the number of claims we have assumed for the 2018/19 financial year. This approach implicitly assumes that:

- The future rate of incidence of asbestos-related diseases manifesting as a result of a past exposure to asbestos will remain stable;
- The pattern of diagnosis and the delay between diagnosis and reporting remain stable;
- The “propensity to claim” by individuals will remain stable; and
- The rate of co-joining the Liable Entities in common law claims will remain stable.
Changes to any of these factors over time will result in changes to the actual pattern of incidence of claims reporting.

The claim curve index also provides us with the proportions of the total number of claims reported in each future year that relate to each of the four age groups for mesothelioma.

Our assumptions for the base number of claims projected to be reported in 2018/19 are summarised in Section 4.4 and Section 5.7.

3.5 Incidence of claim settlements from future claim notifications

We derive a settlement pattern by analysing triangulations of the numbers of settlements and claims payments by delay from the year of notification.

From these settlement pattern analyses, we have estimated the pace at which claims notified in the future will settle, and used this to project the future number, and monetary amount, of settlements in each financial year for each disease type.

Our analysis and assumptions selected are summarised in Section 9.5.

3.6 Average claim costs of IBNR claims

3.6.1 Attritional claims

We define a large claim as one for which the award is greater than or equal to $1m in 2006/07 money terms (which equates to approximately $1.54m in mid 2017/18 money terms).

We define an attritional claim as a non-nil, non-large claim. We define a nil claim as one for which the award payable by the relevant Liable Entity is zero.

We have estimated the following five components to the average cost assessment:

- Average award (sometimes including plaintiff legal costs) of a non-nil “attritional” claim.
- Average plaintiff legal / other costs of a non-nil “attritional” claim.
- Average defence legal costs of a non-nil “attritional” claim.
- Average defence legal costs of a nil claim.
- Large claim awards and legal cost allowances.

All of our analyses have been constructed using past average awards, which have been inflated to mid 2017/18 money terms using a historical base inflation index (of 4% per annum). This allows for basic inflation effects when identifying trends in historical average settlements. We then determine a prospective average cost in mid 2017/18 money terms.

Our analysis and assumptions are summarised in Section 7.

3.6.2 Large claims loading

We analyse the historical incidence rate of large claims (being measured as the ratio of the number of large claims to the total number of non-nil claims), and the average claim size and legal costs of these claims.
We use these to arrive at a “per claim” loading (being the average large claim cost multiplied by the large claim incidence rate per claim), being the additional amount we need to add to our attritional average claim size to allow for large claims.

We have derived separate incidence rate and average claim size assumptions for each of the four age groups for mesothelioma.

Our analysis and assumptions are summarised in Section 7.8.

3.6.3 Future inflation of average claim sizes

Allowance for future claim cost inflation is made. This is modelled as a combination of base inflation plus superimposed inflation. This enables us to project future average settlement costs in each future year, which can then be applied to the IBNR claims numbers as they settle in each future year.

Our analysis and assumptions in relation to claims inflation are summarised in Section 9.2.

3.7 Proportion of claims settled for nil amounts

We apply a “nil settlement rate” to the overall number of settlements to estimate the number of claims which will be settled for nil claim cost (i.e. other than in relation to defence legal costs) and those which will be settled for a non-nil claim cost.

The prospective nil settlement rate is estimated by reference to the analysis of past trends in the rate of nil settlements.

Our analysis and assumptions selected are summarised in Section 8.
3.8 Pending claims

3.8.1 Definition of pending claims

At 31 March 2018, there were 377 claims (31 March 2017: 393) for which claim awards have not yet been fully settled by the Liable Entities.

Additionally, there are a number of other claims for which defence legal costs have not yet been settled, even though the awards have been settled.

We have adopted three definitions of settlement status:

- Where there is a closure date, there are not expected to be any further award or legal costs incurred.
- Where there is no closure date but the claim has a settlement date, there is the possibility of further emerging defendant legal costs, even though the claim award has been settled.
- Where there is no settlement date, there is the possibility of award, plaintiff legal costs and defendant legal costs being incurred.

3.8.2 Evaluating the liability for pending claims

The excess amount of the liability for pending claims, over the case estimates held, is what the insurance industry terms Incurred But Not Enough Reported ("IBNER").

Depending on the case estimation procedure of a company and the nature of the liabilities, IBNER can be either positive or negative, with a negative IBNER implying that the ultimate cost of settling claims will be less than case estimates, i.e. that there is some degree of redundancy in case estimates.

3.8.3 Findings

The table below shows that there has been no deterioration compared to the estimates we previously adopted and are currently adopting (both of which have already made allowance for a 25% saving on case estimates).

Table 3.2: Change in cost of claims during 2017/18 financial year ($m) – claim award component only

<table>
<thead>
<tr>
<th>Figures in $ millions</th>
<th>Current year reported claims</th>
<th>Prior year reported claims</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Estimates for pending claims at 31 March 2017 (undiscounted)</td>
<td>0.0</td>
<td>72.3</td>
<td>72.3</td>
</tr>
<tr>
<td>Paid in the year to 31 March 2018</td>
<td>72.8</td>
<td>52.6</td>
<td>125.4</td>
</tr>
<tr>
<td>Estimates for pending claims at 31 March 2018 (undiscounted)</td>
<td>54.3</td>
<td>11.3</td>
<td>65.6</td>
</tr>
<tr>
<td>Incurred Cost in the financial year</td>
<td>127.1</td>
<td>(8.4)</td>
<td>118.7</td>
</tr>
</tbody>
</table>

The table above shows that there has been a saving of $8.4m in the case estimates for claims that were reported prior to 31 March 2017.

We have maintained our assumption for the level of redundancy in case estimates on currently reported claims at 25% at this valuation (March 2017: 25%). This assumption is only applied to the case estimates for the claim award, i.e. it is not applied to plaintiff/other costs or defence costs.
3.9 Insurance Recoveries

Insurance Recoveries are defined as proceeds which are estimated to be recoverable under the product and public liability insurance policies of the Liable Entities, and therefore exclude any such proceeds from a Workers Compensation Scheme or Policy in which the Liable Entities participate or which the Liable Entities hold.

In applying the insurance programme we therefore consider only the projected gross cashflows relating to product and public liability claims.

Historical analysis of the claims data suggests that approximately 97.5% of all liability claims by cost have been product liability claims.

3.9.1 Programme overview

Until 31 May 1986, the Liable Entities had in place product and public liability insurance policies that were placed on a claims occurring basis.

Product liability claims were insured under these insurance policies on an “in the aggregate” basis whilst public liability claims were insured on an “each and every loss” basis.

From 31 May 1986, the insurance policies were placed on a claims made basis in relation to asbestos-related product and public liability cover.

In summary, the insurance policies were placed as follows:

- For the period up to June 1976, the insurance policies were written on a claims occurring basis. The insurance was provided by QBE but the cover provided by these policies was commuted in June 2000 for a consideration of $3.1m per annum for the following 15 years (through to 30 June 2014). Therefore we have assumed no future insurance recoveries from these policies.

- For the period from June 1976 to 31 May 1986, the insurance policies were written on a claims occurring basis; insured by Lloyds’ of London, London Market insurers, Australian insurers and HIH entities.

- For the period 31 May 1986 to 31 March 1997, the insurance policies were written on a claims-made basis. For the purpose of this Report, we have made no allowance for any Insurance Recoveries arising from these policies.

3.9.2 Modelling insurance recoveries on the claims occurring programme

Our methodology for projecting the future insurance recoveries to be collected by AICFL involves the following steps:

- Identify the current contract positions for each insurance policy year. This assumes that all monies due have been collected, and does not allow for the impact of commutations that have taken place.

- Allocate the projected future gross cashflows to individual insurance policy years using an allocation basis that has been determined by reference to the exposure methodology used to project future claim numbers and also using a “period of exposure” and “time on risk” allocation.
- This gives a projection of how the insurance programme is utilised over time.

This method allows us to:

- evaluate the total insurance recoveries due by payment year;
- determine how the insurance recoveries due will be assigned to each layer and therefore to each insurer; and
- identify and allow for when the individual layers are projected to be fully exhausted.

We then make an additional adjustment to the projected recoveries to exclude those projected future insurance recoveries that are assigned to the participations of insurers who have already commuted their coverage with AICFL and the Liable Entities or insurers who have settled their coverage by way of a Scheme of Arrangement.

3.9.3 Commutations, HIH and Schemes of Arrangement

Other commutations have been entered into by AICFL in previous years and these commutations have typically (other than QBE) involved the payment of a lump sum amount.

In these circumstances, we have assumed that the insurance liabilities of that company to the Liable Entities have been fully discharged and no further recoveries will fall due.

We have assumed that all monies have been paid in relation to insurance recoveries for the claims occurring period from HIH. Any future insurance proceeds from HIH are not expected to be material.

For the claims occurring period, where a claim filed against a company under a Scheme of Arrangement has been accepted and payment made, we have assumed that the insurance liabilities of that company to the Liable Entities have been fully discharged and no further recoveries will fall due.

We have made no allowance or adjustment in our valuation for any potential future commutations.

3.9.4 Unpaid insurance recoveries

We have not included within our liability estimate any allowance for insurance recoveries under the claims occurring period that are due but have not yet been collected.

We are advised that such monies amount to approximately $1m at 31 March 2018.

These amounts are more appropriately dealt with as being debtors of AICFL.

3.9.5 Bad and doubtful debt allowance on Insurance Recoveries

We have made allowance for bad and doubtful debts on future Insurance Recoveries within our valuation by use of the default rates as shown in the table below.
Table 3.3: Credit rating default rates by duration

<table>
<thead>
<tr>
<th>Rating</th>
<th>Yr. 1</th>
<th>Yr. 2</th>
<th>Yr. 3</th>
<th>Yr. 4</th>
<th>Yr. 5</th>
<th>Yr. 6</th>
<th>Yr. 7</th>
<th>Yr. 8</th>
<th>Yr. 9</th>
<th>Yr. 10</th>
<th>Yr. 11</th>
<th>Yr. 12</th>
<th>Yr. 13</th>
<th>Yr. 14</th>
<th>Yr. 15</th>
</tr>
</thead>
<tbody>
<tr>
<td>AAA</td>
<td>0.00%</td>
<td>0.03%</td>
<td>0.13%</td>
<td>0.24%</td>
<td>0.35%</td>
<td>0.46%</td>
<td>0.52%</td>
<td>0.50%</td>
<td>0.54%</td>
<td>0.72%</td>
<td>0.75%</td>
<td>0.78%</td>
<td>0.81%</td>
<td>0.83%</td>
<td>0.94%</td>
</tr>
<tr>
<td>AA+</td>
<td>0.00%</td>
<td>0.05%</td>
<td>0.09%</td>
<td>0.11%</td>
<td>0.16%</td>
<td>0.22%</td>
<td>0.28%</td>
<td>0.33%</td>
<td>0.40%</td>
<td>0.46%</td>
<td>0.52%</td>
<td>0.59%</td>
<td>0.63%</td>
<td>0.72%</td>
<td>0.79%</td>
</tr>
<tr>
<td>AA</td>
<td>0.02%</td>
<td>0.03%</td>
<td>0.09%</td>
<td>0.12%</td>
<td>0.23%</td>
<td>0.49%</td>
<td>0.62%</td>
<td>0.73%</td>
<td>0.83%</td>
<td>0.93%</td>
<td>1.01%</td>
<td>1.08%</td>
<td>1.19%</td>
<td>1.26%</td>
<td>1.33%</td>
</tr>
<tr>
<td>AA-</td>
<td>0.03%</td>
<td>0.09%</td>
<td>0.18%</td>
<td>0.26%</td>
<td>0.35%</td>
<td>0.47%</td>
<td>0.54%</td>
<td>0.60%</td>
<td>0.66%</td>
<td>0.72%</td>
<td>0.78%</td>
<td>0.85%</td>
<td>0.88%</td>
<td>0.93%</td>
<td>0.98%</td>
</tr>
<tr>
<td>A+</td>
<td>0.05%</td>
<td>0.10%</td>
<td>0.21%</td>
<td>0.35%</td>
<td>0.47%</td>
<td>0.57%</td>
<td>0.69%</td>
<td>0.82%</td>
<td>0.97%</td>
<td>1.12%</td>
<td>1.27%</td>
<td>1.43%</td>
<td>1.61%</td>
<td>1.83%</td>
<td>2.01%</td>
</tr>
<tr>
<td>A</td>
<td>0.06%</td>
<td>0.10%</td>
<td>0.23%</td>
<td>0.37%</td>
<td>0.51%</td>
<td>0.71%</td>
<td>0.90%</td>
<td>1.08%</td>
<td>1.29%</td>
<td>1.53%</td>
<td>1.79%</td>
<td>1.89%</td>
<td>2.03%</td>
<td>2.13%</td>
<td>2.21%</td>
</tr>
<tr>
<td>A-</td>
<td>0.07%</td>
<td>0.18%</td>
<td>0.29%</td>
<td>0.42%</td>
<td>0.60%</td>
<td>0.78%</td>
<td>1.04%</td>
<td>1.23%</td>
<td>1.38%</td>
<td>1.51%</td>
<td>1.63%</td>
<td>1.79%</td>
<td>1.94%</td>
<td>2.08%</td>
<td>2.19%</td>
</tr>
<tr>
<td>BBB+</td>
<td>0.12%</td>
<td>0.32%</td>
<td>0.56%</td>
<td>0.82%</td>
<td>1.08%</td>
<td>1.39%</td>
<td>1.63%</td>
<td>1.88%</td>
<td>2.16%</td>
<td>2.44%</td>
<td>2.72%</td>
<td>2.92%</td>
<td>3.18%</td>
<td>3.51%</td>
<td>3.88%</td>
</tr>
<tr>
<td>NR</td>
<td>3.83%</td>
<td>7.48%</td>
<td>10.63%</td>
<td>12.20%</td>
<td>13.29%</td>
<td>13.01%</td>
<td>13.85%</td>
<td>15.65%</td>
<td>20.71%</td>
<td>21.67%</td>
<td>22.47%</td>
<td>23.13%</td>
<td>24.27%</td>
<td>25.17%</td>
<td>24.80%</td>
</tr>
<tr>
<td>R</td>
<td>100.00%</td>
<td>100.00%</td>
<td>100.00%</td>
<td>100.00%</td>
<td>100.00%</td>
<td>100.00%</td>
<td>100.00%</td>
<td>100.00%</td>
<td>100.00%</td>
<td>100.00%</td>
<td>100.00%</td>
<td>100.00%</td>
<td>100.00%</td>
<td>100.00%</td>
<td>100.00</td>
</tr>
</tbody>
</table>


NR relates to companies which are Not Rated

R relates to companies which have been subject to Regulatory Action regarding solvency.

We have considered the credit rating of the insurers (and/or their parent companies) of the Liable Entities as at March 2018 and applied the relevant credit rating default rates to the expected future cashflows by year, treaty and insurer.

3.10 Cross-claim recoveries

A cross-claim can be brought by, or against, one or more Liable Entities. Cross-claims brought against a Liable Entity (“Contribution Claims”) are included in our analysis of the claims experience.

Cross-claims brought by a Liable Entity relate to circumstances where the Liable Entity seeks to join (as a cross-defendant) another party to the claim in which the Liable Entity is already joined.

Our approach in the valuation has been to separately value the rate of recovery (“cross-claims recovery rate”) as a percentage of the gross award based on historical experience of such recoveries.

Our analysis and assumptions selected are summarised in Section 9.4.

3.11 Discounting cashflows

Cashflows are discounted on the basis of yields available at the valuation date on Commonwealth of Australia fixed interest Government Bonds (“Commonwealth Government Bonds”) of varying coupon rates and durations to maturity.

Our approach to the determination of the discount rates is unchanged from the approach adopted at 31 March 2017, and is:

- For years 1 to 16, zero coupon spot rates were determined by reference to the prices, coupons and durations of Commonwealth Government Bonds;
- For years 19 and onwards, we have selected a uniform long-term discount rate of 5.50% per annum; and
- For years 17 and 18, we have selected spot rates that “linearly interpolate” between the year-16 rate and the year-19 rate (of 5.50%).

Our selected assumptions are summarised in Section 9.3.
4. Claims Experience: Mesothelioma Claim Numbers

4.1 Overview

The following chart shows the number of mesothelioma claims reported by year of notification.

Figure 4.1: Number of mesothelioma claims reported annually

Note: Throughout Sections 4 to 9, the date convention used in tables and charts is that (for example) 2008/09 indicates the financial year running from 1 April 2008 to 31 March 2009. Furthermore, unless clearly identifying a calendar year, the label “2008” in charts or tables would indicate the financial year running from 1 April 2008 to 31 March 2009.

Three successive years of increases in claims reporting after 2011/12 through to 2014/15 were followed by two years of reductions in claims reporting activity through to 2016/17.

For 2017/18, there were 392 mesothelioma claims reported. This represented a 5% increase relative to the prior year.
4.1.1 Monthly analysis of notifications

We have examined the number of mesothelioma claims reported on a monthly basis to better understand the nature of the claims experience observed on an annual basis.

Figure 4.2: Monthly notifications of mesothelioma claims

It is observed that:

- August 2017 represented the highest claims reporting activity in the 2017/18 year, with 44 claims reported in that month.
- In 2017/18, four months of the year had 30 or fewer claims reported.

4.1.2 Rolling averages

We have reviewed the number of mesothelioma claims reported on a monthly basis and reviewed the rolling 3-month, 6-month and 12-month averages in recent periods.

Figure 4.3: Rolling annualised averages of mesothelioma claim notifications
4.2 Profile of mesothelioma claims

4.2.1 Claims by State

We have analysed the number of mesothelioma claim notifications by the State in which the claim is filed.

Figure 4.4: Number of mesothelioma claims by State

NSW is the largest State in terms of claims reporting activity for mesothelioma claims. Typically NSW represents between 40% and 45% of all mesothelioma claims.

4.2.2 Direct claims and cross-claims

The following chart shows the number of claims notified by year of notification and separately as between claims brought by claimants (which we refer to as ‘direct claims’) and claims brought by other defendants, some of which are brought a number of years after the claim was first notified (these claims we refer to as ‘cross claims’).

Figure 4.5: Number of mesothelioma claims by type of claim
The increase in claim numbers arising from cross-claims that was observed in 2012/13 has continued with the number of cross claims reported in the last five financial years remaining at a similar level to 2012/13.

NSW is currently the primary source of cross claims (making up approximately 65% of the total number of cross claims in 2017/18).

In 2017/18, the increase in the number of direct claims was primarily attributable to higher claims reporting in WA and SA.

4.2.3 Source of claims

We have analysed the number of mesothelioma claims according to whether they involve renovation activity or not.

It should be noted that these claims can involve both short periods and long periods of exposure and that the definition used in the chart below also includes other family and home exposures (e.g. family members involved in washing clothes of people who were using asbestos products).

The number of non-renovator claims has been broadly stable over the five years from 2013/14 to 2017/18.

The chart shows that the number of renovator claims showed a significant increase from 2011/12 to 2014/15 but has since moderated, albeit remaining at levels higher than previously observed.

Figure 4.6: Number of mesothelioma claims by source of claim

![Chart showing number of mesothelioma claims by source of claim from 2007 to 2017. The x-axis represents the year of notification, and the y-axis represents the number of claims. The chart shows a significant increase in renovator claims from 2011/12 to 2014/15, followed by a moderation in numbers. Non-renovator claims have been broadly stable over the five years.]
4.2.4 Number of defendants

The following chart shows the number of claims notified by year of notification and by number of defendants.

Figure 4.7: Number of mesothelioma claims by number of defendants (direct claims only)

The number of claims reported involving only the Liable Entities (i.e. single-defendant claims) showed considerable increases between 2011/12 and 2014/15.

Claims in which the Liable Entities are the only defendants to the claim are typically associated with higher average claim sizes whilst claims involving multiple defendants typically involve the Liable Entities paying 60% or less of the total settlement (see Section 7.2).

This feature is a contributor to the trends in average claim sizes experienced in the last four years.
4.2.5 Age profile of claimants

The following charts show the numbers and proportions of claims reported for each of the four age groups of claimants.

Figure 4.8: Proportion of mesothelioma claims by age of claimant

The proportion of claims reported involving claimants over the age of 70 has gradually increased, evident by the downwards trends in the chart from left to right.

Figure 4.9: Number of mesothelioma claims by age of claimant

In absolute terms, the number of claims arising from claimants aged 70 years or older rose by 43% from 189 in 2012/13 to 271 in 2017/18.

By contrast, the number of claims arising from claimants aged less than 70 years has remained relatively unchanged (115 in 2012/13 compared to 117 in 2017/18).

There are currently 4 claims notified in 2017/18 where the age of claimant is not yet known to the Liable Entities.
The growth in overall mesothelioma claim numbers in recent years has therefore primarily arisen from claimants aged 70 or older.

The higher proportion (and number) of claims involving claimants over 70 years of age has been a contributor to the trends in average claim sizes experienced in the last ten years (thereby acting to offset other claims inflation drivers) and in particular the reductions in average claim sizes experienced in the last five years.

4.2.6 Delay from diagnosis to notification

The chart below measures the time-lag (in days) from diagnosis of mesothelioma to notification of a claim against the Liable Entities. The chart shows that direct claims are reported more quickly than cross-claims.

Direct claims have typically taken between 5 months and 7 months to be reported after diagnosis of mesothelioma.

Figure 4.10: Delay from diagnosis of mesothelioma to notification of claim against the Liable Entities

There has been a significant speed up in claims reporting for direct claims in 2016/17 and 2017/18.

The average time between diagnosis to notification reduced to approximately 4 months in 2017/18, and this represents the lowest level observed by AICF since its formation.
4.3 External statistics on mesothelioma claims incidence

The following chart compares the total number of mesothelioma cases reported (diagnosed) nationally to the number of mesothelioma claims received by the Liable Entities.

It should be noted that the two sets of data correspond to different definitions of year and so are not directly comparable and some caution should be exercised.

The “year” is calendar year for the national cases (i.e. 2012 is the year running from 1 January 2012 to 31 December 2012); whilst for the Liable Entities it is the financial year (i.e. 2012 is the year running from 1 April 2012 to 31 March 2013).

Figure 4.11: Number of mesothelioma cases reported nationally compared to the number of claims received by the Liable Entities

Annual Report of the Australian Mesothelioma Registry for 2014 and onwards

The annual number of mesothelioma cases diagnosed nationally was relatively stable for the period 2007 to 2011 varying between 667 and 701 cases.

In calendar year 2016, the number of cases diagnosed nationally (as currently reported) fell to 700. It should be noted there may be a considerable degree of under-reporting in the 2016 year and, to a lesser extent, the 2015 year, noting that:

- The 2013 year was initially reported as 575, and this increased to 676 (as reported in the 2014 Australian Mesothelioma Registry Report) and is 705 (as reported in the 2016 Australian Mesothelioma Registry Report); and
- The 2014 year was first reported as 641 and this increased to 732 (as reported in the 2015 Australian Mesothelioma Registry Report) and to 756 (as reported in the 2016 Australian Mesothelioma Registry Report).

These increases in national statistics lead to a lower ratio for the number of Liable Entity claims as a percentage of the number of national cases of mesothelioma. As a consequence the currently estimated 54% for 2016/17 may be over-stated and (if previous experience of
initial under-reporting of the number of national cases were to recur) may be more in the order of 50%.

It should be noted that not all cases of mesothelioma result in a claim being brought in Common Law. Furthermore, even if a claim is brought, not all claims will involve the Liable Entities.

In relation to NSW, we have additional information from the Dust Diseases Tribunal (NSW) that indicates what proportion of common law claims the Liable Entities are joined in for NSW.

For the DDB/DDA data, the “year” is financial year (i.e. 2012 is the year running from 1 July 2012 to 30 June 2013). In contrast, in the DDT data, “year” is defined as a calendar year (i.e. 2012 is the year running from 1 January 2012 to 31 December 2012). It should be noted that the four sets of data correspond to different definitions of year and so are not directly comparable and some caution should be exercised.

**Figure 4.12: Number of mesothelioma cases reported in NSW**

![Graph showing number of mesothelioma cases reported in NSW]

Australian Mesothelioma Registry for 2013-2016.
Insurance and Care NSW Annual Report 2016-17.
DDT statistics provided by the State of New South Wales

The chart shows that whilst the number of NSW cases of mesothelioma has been relatively stable, other than the 12% increase in 2016, and that the DDB/DDA has shown a similar trend, the number of common law DDT cases has risen by more than 45% between 2007 and 2017. The Liable Entities have experienced a broadly similar rate of growth.

The data would appear to indicate that the Liable Entities are not being increasingly joined in common law claims in NSW, nor that there is necessarily an increasing prevalence of mesothelioma in NSW, but rather that the proportion of people being diagnosed who then bring a common law claim is the primary factor leading to the increases in claim numbers that have been observed in the last ten years (i.e. there has been an increase in the propensity to claim).
The chart below shows the mix of national cases by age. The data shows a broadly similar pattern to AICF’s own experience (see Figure 4.8), with the proportion of cases relating to people under 70 years of age trending down and currently comprising around 30% of all cases.

Figure 4.13: Age profile of mesothelioma cases nationally

![Age profile chart](chart.png)

Sources: Australian Institute of Health and Welfare; Australian Mesothelioma Registry Report

### 4.4 Base valuation assumption for number of mesothelioma claims

The actual claims reporting experience in 2017/18 has been adverse compared to expectations for 2017/18 in relation to overall mesothelioma claim numbers.

As a consequence of this, we have increased our valuation assumption for 2018/19 from 353 claims (as previously assumed for 2018/19, based on an assumption of 372 claims for 2017/18) to 390 claims.

The assumption for 2018/19 has been set having regard to the average of the last three years of claims reporting.

There remain material uncertainties in relation to the base level of claims reporting and it is possible that claims activity could increase next year, or fall next year.

There also remain material uncertainties as to the pace at which future claims reporting will reduce ("the decay rate") as well as the rate of co-joining of the Liable Entities in common law claims.

Depending on the outcome of future experience, further changes to the valuation assumptions and therefore to the valuation results may be necessary in future periods. Such changes could be material.

As a consequence of the above noted uncertainties, further volatility in relation to the valuation result should be anticipated.

Given the application of the new method, the proportion of claims emerging in each of the four age groups is also a key factor in relation to the valuation of the liabilities at future valuation periods.
5. Claims Experience: Claim numbers (non-mesothelioma)

5.1 Overview

The table below shows the number of claims reported by year of notification and by disease category.

Table 5.1: Number of claims by disease type

<table>
<thead>
<tr>
<th>Year of notification</th>
<th>Asbestosis</th>
<th>Lung Cancer</th>
<th>ARPD &amp; Other</th>
<th>Wharf</th>
<th>Workers</th>
</tr>
</thead>
<tbody>
<tr>
<td>2007</td>
<td>171</td>
<td>28</td>
<td>43</td>
<td>8</td>
<td>46</td>
</tr>
<tr>
<td>2008</td>
<td>163</td>
<td>40</td>
<td>44</td>
<td>11</td>
<td>59</td>
</tr>
<tr>
<td>2009</td>
<td>120</td>
<td>40</td>
<td>43</td>
<td>3</td>
<td>61</td>
</tr>
<tr>
<td>2010</td>
<td>140</td>
<td>13</td>
<td>36</td>
<td>9</td>
<td>30</td>
</tr>
<tr>
<td>2011</td>
<td>110</td>
<td>15</td>
<td>36</td>
<td>6</td>
<td>30</td>
</tr>
<tr>
<td>2012</td>
<td>128</td>
<td>33</td>
<td>38</td>
<td>7</td>
<td>27</td>
</tr>
<tr>
<td>2013</td>
<td>117</td>
<td>26</td>
<td>49</td>
<td>15</td>
<td>32</td>
</tr>
<tr>
<td>2014</td>
<td>144</td>
<td>25</td>
<td>39</td>
<td>11</td>
<td>34</td>
</tr>
<tr>
<td>2015</td>
<td>90</td>
<td>19</td>
<td>31</td>
<td>11</td>
<td>29</td>
</tr>
<tr>
<td>2016</td>
<td>97</td>
<td>19</td>
<td>32</td>
<td>11</td>
<td>24</td>
</tr>
<tr>
<td>2017</td>
<td>85</td>
<td>26</td>
<td>31</td>
<td>9</td>
<td>20</td>
</tr>
<tr>
<td>2007-2017</td>
<td>1,365</td>
<td>284</td>
<td>422</td>
<td>100</td>
<td>382</td>
</tr>
<tr>
<td>All Years</td>
<td>2,378</td>
<td>633</td>
<td>791</td>
<td>230</td>
<td>1,405</td>
</tr>
</tbody>
</table>

5.2 Asbestosis claims

For asbestosis, the most recent three years of claims reporting have seen claims reporting below 100 claims for each year.

This is in contrast to the previous three years which averaged 130 claims.

In selecting our assumption for 2018/19, we have (in broad terms) taken the average of the last three years as a base level.

We have assumed 96 asbestosis claims will be reported in 2018/19.

5.3 Lung cancer claims

The number of lung cancer claims reported has typically been between 25 and 40 claims per annum.

In 2015/16, the number of claims reported fell to 19 and in 2016/17 it remained at 19 claims. In 2017/18, there was an increase to 26 claims.

We have assumed 24 lung cancer claims will be reported in 2018/19.
5.4 ARPD & Other claims

The number of ARPD & Other claims has averaged 31 claims over the last three years. This is in contrast to the previous three years which averaged 42 claims.

In selecting our assumption for 2018/19, we have (in broad terms) taken the average of the last three years as a base level.

We have assumed 30 ARPD & Other claims will be reported in 2018/19.

5.5 Workers Compensation claims

The number of Workers Compensation claims, including those met in full by the Liable Entities’ Workers Compensation insurers, has historically exhibited some degree of volatility. However claims reporting activity has been relatively stable for the last eight years, albeit showing a reduction to 20 claims in 2017/18.

We have assumed 24 Workers Compensation claims will be reported in 2018/19.

It should be noted that the financial impact of this source of claim is not substantial to the Liable Entities given the proportion of claims which are settled for nil liability against the Liable Entities (typically above 90%), which results from the insurance arrangements in place.

5.6 Wharf claims

For Wharf claims, there were 8 claims reported in 2017/18 and 11 claims were reported in each of the previous three years.

We have assumed 12 claims will be notified in 2018/19.

Again, the financial impact of this source of claim is not currently significant.

5.7 Summary of base claims numbers assumptions (including mesothelioma)

As outlined in Sections 4 and 5, our assumptions as to the number of claims to be reported in 2018/19 are as follows:

Table 5.2: Claim numbers experience and assumptions for 2018/19

<table>
<thead>
<tr>
<th></th>
<th>FY17 actual</th>
<th>FY18 actual</th>
<th>FY18 expected</th>
<th>FY19 Assumption</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mesothelioma</td>
<td>374</td>
<td>392</td>
<td>372</td>
<td>390</td>
</tr>
<tr>
<td>Asbestosis</td>
<td>97</td>
<td>85</td>
<td>108</td>
<td>96</td>
</tr>
<tr>
<td>Lung Cancer</td>
<td>19</td>
<td>26</td>
<td>21</td>
<td>24</td>
</tr>
<tr>
<td>ARPD &amp; Other</td>
<td>32</td>
<td>31</td>
<td>33</td>
<td>30</td>
</tr>
<tr>
<td>Wharf</td>
<td>11</td>
<td>8</td>
<td>12</td>
<td>12</td>
</tr>
<tr>
<td>Worker</td>
<td>24</td>
<td>20</td>
<td>30</td>
<td>24</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>557</strong></td>
<td><strong>562</strong></td>
<td><strong>576</strong></td>
<td><strong>576</strong></td>
</tr>
</tbody>
</table>

*FY18 Expected is the assumption selected for 2017/18 in our previous valuation report.*
5.8 Baryulgil

Almost half of the claims settled which relate to asbestos mining activities at Baryulgil (as discussed previously in Section 1.2.3) have been settled with no liability against the Liable Entities; and for the remaining settled claims, the Liable Entities have typically borne one-third to one-half of the settlement amount, reflecting the contribution by other defendants to the overall settlement (including those which have since been placed in liquidation).

For the purposes of our valuation, we have estimated there to be 10 future claims reported, comprising 7 mesothelioma claims and 3 non-mesothelioma claims.

We have assumed average claims and legal costs broadly in line with those described in Section 7.

Our projected liability assessment at 31 March 2018 of the additional provision (for claims not yet reported) that could potentially be required is an undiscounted liability of $2.9m and a discounted liability of $2.5m, all of which is deemed to be a liability of Amaca.
6. Exposure and Latency

Experience and Incidence Pattern

Assumptions

6.1 Mesothelioma claims experience

6.1.1 Exposure information from claims notified to date

We have reviewed the actual exposure information available for claims notified to date. This has been conducted by using the exposure dates stored in the claims database at an individual claim level and identifying the number of person-years of exposure in each exposure year.

Figure 6.1: Exposure (person-years) of all Liable Entities’ mesothelioma claimants to date

The chart shows that, currently, the peak year of exposure for claims reported to date is in 1972.

It should be recognised that there is a degree of bias in this analysis in that the claims notified to date will tend to have arisen from the earlier periods of exposure.

Over time, we expect the right-hand side of this curve to develop and the peak year of exposure to trend towards the early-1970s to mid-1970s, and an increase in the absolute level at all periods of exposure as more claims are notified and the associated exposures from these are included in the analysis.
The relatively low level of exposure from 1987 onwards (about 5% of the total) is not unexpected given that all asbestos products ceased being manufactured by the Liable Entities by 1987. The exposure after that date likely results from usage of products already produced and sold before that date.

The chart above is a cumulative chart of the position to date and does not show temporal trends in the allocation of claims to exposure years.

For example, one would expect that more recently reported claims should be associated with, on average, later exposures; and that claims reported in future years would continue that trend towards later exposure periods.

To understand better these temporal trends, we have modelled claimants’ exposures for each past claim report year.

Figure 6.2: Exposure (person years) of all mesothelioma claimants to date by report year and exposure period

As can be seen in the chart above, there has been a general increasing shift towards the exposure period after 1970, evident by the downwards trends in the chart from left to right indicating that an increasing proportion of the claimants’ exposure relates to more recent exposure periods.

For example, pre-1970 exposures made up approximately 45% of mesothelioma claims exposures in 2007/08 but less than 32% of claims exposures in 2017/18.

We would expect that such a trend should continue for some time to come and that an increasing proportion of the exposure (in relation to future reported claims) will relate to the period 1981/82 to 1985/86.

6.1.2 Latency period of reported claims

We have analysed the actual latency period of the reported claims of the Liable Entities. In the charts that follow, we have measured the average actual latency period from the average date of exposure to the date of notification of a claim.
The chart below shows the average latency observed for mesothelioma claims and the 25th percentile and 75th percentile observations.

**Figure 6.3: Latency of mesothelioma claims**

The above chart indicates that the observed average latency period from the average exposure is currently approximately 44 years for mesothelioma, and has shown an increase over time.

**Figure 6.4: Latency distribution of mesothelioma claims (all years)**

Our latency model assumes a “normal distribution” and the chart above seems to (in broad terms) support that assumption at this time, with both the mean latency to date and the median latency to date being 38 years and the mode of the latency being 40 years.

Over the past ten years, the observed average latency of mesothelioma claims reported in a report year has increased from 38 years to 44 years, increasing at a rate of about 0.6 years with every year that passes.
The observed average latency of claims reported in future report years should also be expected to show a further upward trend in the coming years.

The currently observed standard deviation of the latency period is 8 years.

Some of the increase in average reported latencies over time has been a consequence of the changing mix of claims by age of claimant. Older claimants are typically associated with longer latencies.

As discussed elsewhere in this report, the proportion of claims arising from older age groups has been increasing.

The following chart shows how the average reported latencies vary between each of the age groups.

Figure 6.5: Latency of mesothelioma claims by age of claimant

![Latency of mesothelioma claims by age of claimant chart]

The claims experience to date and the assumptions selected seem to broadly accord with epidemiological research in relation to mesothelioma, once the relevant adjustments to standardise onto a consistent terminology are made.

Our revised latency model for mesothelioma from first exposure assumes a mean latency of 40 years and a standard deviation of 9 years.

An indication of how different assumptions would affect the incidence curve and therefore the number of IBNR claims is as follows:

- A higher mean latency period would increase the peak period of claims reporting and would give rise to a higher number of IBNR claims.
- A lower standard deviation would lead to a faster decay in the number of claims being reported after the peak period of claims reporting and would give rise to a lower number of IBNR claims.

The increase in the overall mean latencies that we have adopted at this valuation gives rise to more claims by number at older ages and also gives rise to a slower rate of decay of the numbers of claims in future reporting periods, most notable in the years after 2025.
6.2 Mesothelioma incidence patterns

6.2.1 Overall future incidence pattern and IBNR claim numbers

The following chart shows the pattern of future notifications which have resulted from the application of our revised methodology (labelled “Model 2”). It also shows how the projections under the previous valuation approach compare, including both last year’s valuation (labelled “FY17 projection”) and what that would have become by simply applying the revised view of 2018/19 (labelled “Model 1: FY17 projection rebased”).

Figure 6.6: Projected future claim notifications for mesothelioma

The table below summarises the number of future claims projected to be reported for mesothelioma under the current valuation approach and also compares with the previous adopted approach.

Table 6.1: Projected future claim notifications for mesothelioma

<table>
<thead>
<tr>
<th>Claim Number Projections</th>
<th>FY2017 Valuation</th>
<th>FY2017 Valuation with new base value</th>
<th>Current Valuation</th>
<th>Impact of Modelling Change</th>
<th>Impact of Modelling Change (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>FY2018</td>
<td>372</td>
<td>392</td>
<td>392</td>
<td>0</td>
<td>0%</td>
</tr>
<tr>
<td>FY2019</td>
<td>353</td>
<td>390</td>
<td>390</td>
<td>0</td>
<td>0%</td>
</tr>
<tr>
<td>FY2020</td>
<td>329</td>
<td>363</td>
<td>378</td>
<td>16</td>
<td>4%</td>
</tr>
<tr>
<td>FY21 - FY25</td>
<td>1,202</td>
<td>1,327</td>
<td>1,573</td>
<td>246</td>
<td>19%</td>
</tr>
<tr>
<td>FY26 - FY30</td>
<td>578</td>
<td>638</td>
<td>984</td>
<td>346</td>
<td>54%</td>
</tr>
<tr>
<td>FY31 - FY40</td>
<td>332</td>
<td>366</td>
<td>703</td>
<td>337</td>
<td>92%</td>
</tr>
<tr>
<td>FY41 - FY45</td>
<td>29</td>
<td>32</td>
<td>78</td>
<td>46</td>
<td>142%</td>
</tr>
<tr>
<td>1 April 2045 onwards</td>
<td>11</td>
<td>12</td>
<td>30</td>
<td>18</td>
<td>157%</td>
</tr>
<tr>
<td>Total</td>
<td>3,207</td>
<td>3,520</td>
<td>4,528</td>
<td>1,008</td>
<td>29%</td>
</tr>
<tr>
<td>FY2018 to FY2025</td>
<td>2,256</td>
<td>2,471</td>
<td>2,733</td>
<td>262</td>
<td>11%</td>
</tr>
<tr>
<td>FY2026 onwards</td>
<td>950</td>
<td>1,049</td>
<td>1,795</td>
<td>740</td>
<td>71%</td>
</tr>
</tbody>
</table>

Note: Figures may not add “on sight” due to rounding.

The table shows that the previous valuation approach assumed approximately 3,200 claims to be reported from 1 April 2017 onwards.

Taking into account the higher level of claims now being assumed for FY19 and applying that proportionate increase across all future years would have given rise to an estimate of 3,520 claims to be reported from 1 April 2017 onwards.
The new approach (which allows for longer latencies and does not assume that recent experience was one-off in nature) projects a total future number of claims of approximately 4,530.

It can be observed that this additional 29% increase is not a uniform increase across all years but is weighted towards periods after 31 March 2025.

In part, some of this represents the fact that the previous valuation approach had only partly taken into account the recent high level of claims reporting through to 2025 and no adjustment thereafter (this short-term and medium-term adjustment was discussed in detail in our 31 March 2014 valuation report).

6.2.2 Assumed change in future mix of claims by claimant age

Based on the actual mix of claims by claimant age, we have assumed a mix of claims by claimant age for 2018/19 as follows:

- 8.5% for ages less than 60,
- 23.5% for ages 60-70,
- 41% for ages 70-80, and
- 27% for ages over 80.

The following chart shows the change in mix of claims by claimant age over time both historically and projected into the future periods that arises from our revised approach.

**Figure 6.7: Mix of claims by claimant age for mesothelioma**

6.2.3 Inherent uncertainty in future mesothelioma claims reporting

Should mesothelioma claims reporting escalate in future periods, further valuation responses in future years may be necessary.

Additionally, should the mix of claims by claimant age change relative to that assumed, the overall average claim sizes emerging would differ from expected and this might lead to further valuation responses.
6.3 Non-mesothelioma experience

6.3.1 Latency period of reported claims

The trend in latency periods for other disease types is shown in the following charts.

**Figure 6.8: Latency of asbestosis claims**

![Graph showing latency of asbestosis claims](image)

**Figure 6.9: Latency of lung cancer claims**

![Graph showing latency of lung cancer claims](image)
The average observed latency periods for the other disease types show a more surprising trend, appearing to be longer than epidemiological literature has tended to suggest.

A summary of our underlying latency assumptions by disease type are shown below. The mean and standard deviation values quoted are applied to a normal distribution model for the latency period.

Table 6.2: Assumed underlying latency distribution parameters from average date of exposure to date of notification

<table>
<thead>
<tr>
<th>Disease Type</th>
<th>Mean latency (years)</th>
<th>Standard deviation of latency (years)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asbestosis</td>
<td>35</td>
<td>8</td>
</tr>
<tr>
<td>Lung Cancer</td>
<td>35</td>
<td>10</td>
</tr>
<tr>
<td>ARPD &amp; Other</td>
<td>32</td>
<td>10</td>
</tr>
<tr>
<td>Wharf</td>
<td>n/a</td>
<td>n/a</td>
</tr>
<tr>
<td>Workers compensation</td>
<td>n/a</td>
<td>n/a</td>
</tr>
</tbody>
</table>

These assumptions are unchanged from the previous valuation.

6.3.2 Modelled assumptions for peak year of claim incidence

Based on the application of our exposure model and our latency model, and the assumptions contained explicitly or implicitly within those models, the peak year of notification of claims reporting against the Liable Entities for each disease type (excluding mesothelioma) is modelled to be as follows:
Table 6.3: Modelled peak year of claim notifications

<table>
<thead>
<tr>
<th>Disease Type</th>
<th>Current valuation</th>
<th>Previous valuation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asbestosis</td>
<td>2008/09</td>
<td>2008/09</td>
</tr>
<tr>
<td>Lung Cancer</td>
<td>2010/11</td>
<td>2010/11</td>
</tr>
<tr>
<td>ARPD &amp; Other</td>
<td>2007/08</td>
<td>2007/08</td>
</tr>
<tr>
<td>Wharf</td>
<td>2008/09</td>
<td>2008/09</td>
</tr>
<tr>
<td>Workers Compensation</td>
<td>2007/08</td>
<td>2007/08</td>
</tr>
</tbody>
</table>

These modelled assumptions are unchanged and reflect no changes to the exposure data and no changes to the latency model assumptions at this time.

We note that whilst the “modelled peak” derived from our model is as shown above, this does not automatically translate to, nor does it imply that, the “highest claims reporting year” will be those years. This is because variation from year to year is expected due to normal ‘statistical variation’ in claim numbers.

6.3.3 Projected incidence patterns

We have projected the future number of claim notifications from the curve we have derived using our exposure model and our latency model. We have applied this curve to the base number of claims we have estimated for each disease type for 2018/19 as summarised in Section 5.7.

The following chart shows the pattern of future notifications which have resulted from the application of our exposure and latency model and the recalibration of the curve to our revised expectations of claims reporting activity for 2018/19.

Figure 6.11: Projected future claim notifications for other disease types
7. Claims Experience: Average Claims and Legal Costs

7.1 Overview

We have analysed the average claim awards, average plaintiff/other costs and average defendant legal costs by disease type in arriving at our valuation assumptions.

The table below shows how the average settlement cost for non-nil attritional claims has varied by client settlement year. All data have been converted into mid 2017/18 money terms using a historical base inflation index of 4% per annum.

We refer to these amounts as “inflated average attritional awards” in the charts and tables that follow.

The average amounts shown hereafter relate to the average amount of the contribution made by the Liable Entities, and does not reflect the total award payable to the plaintiff unless this is clearly stated to be the case.

In particular, for Workers Compensation the average award reflects the average contribution by the Liable Entities for claims in which they are joined but relates only to that amount of the award determined against the Liable Entities which is not met by a Workers Compensation Scheme or Policy.

Table 7.1: Average attritional non-nil claim award (inflated to mid 2017/18 money terms)

<table>
<thead>
<tr>
<th>Client Settlement Year</th>
<th>Mesothelioma</th>
<th>Asbestos</th>
<th>Lung Cancer</th>
<th>ARPD &amp; Other</th>
<th>Wharf</th>
<th>Workers Compensation</th>
</tr>
</thead>
<tbody>
<tr>
<td>2007</td>
<td>332,306</td>
<td>115,837</td>
<td>162,493</td>
<td>69,844</td>
<td>70,024</td>
<td>386,978</td>
</tr>
<tr>
<td>2008</td>
<td>379,230</td>
<td>122,034</td>
<td>120,131</td>
<td>127,412</td>
<td>205,892</td>
<td>78,282</td>
</tr>
<tr>
<td>2009</td>
<td>338,488</td>
<td>137,062</td>
<td>138,929</td>
<td>120,787</td>
<td>80,565</td>
<td>137,496</td>
</tr>
<tr>
<td>2010</td>
<td>344,130</td>
<td>112,308</td>
<td>180,601</td>
<td>94,991</td>
<td>51,928</td>
<td>0</td>
</tr>
<tr>
<td>2011</td>
<td>361,953</td>
<td>138,162</td>
<td>158,219</td>
<td>123,516</td>
<td>96,278</td>
<td>1,138,787</td>
</tr>
<tr>
<td>2012</td>
<td>356,435</td>
<td>149,077</td>
<td>142,303</td>
<td>105,662</td>
<td>42,808</td>
<td>103,415</td>
</tr>
<tr>
<td>2013</td>
<td>364,626</td>
<td>138,162</td>
<td>121,337</td>
<td>113,837</td>
<td>121,450</td>
<td>23,397</td>
</tr>
<tr>
<td>2014</td>
<td>339,107</td>
<td>111,724</td>
<td>151,027</td>
<td>80,423</td>
<td>90,016</td>
<td>78,740</td>
</tr>
<tr>
<td>2015</td>
<td>319,559</td>
<td>108,753</td>
<td>125,831</td>
<td>111,538</td>
<td>145,772</td>
<td>0</td>
</tr>
<tr>
<td>2016</td>
<td>286,271</td>
<td>81,625</td>
<td>42,336</td>
<td>75,972</td>
<td>38,373</td>
<td>0</td>
</tr>
<tr>
<td>2017</td>
<td>300,491</td>
<td>104,786</td>
<td>117,067</td>
<td>66,285</td>
<td>78,668</td>
<td>241,667</td>
</tr>
</tbody>
</table>
7.2 Mesothelioma claims

7.2.1 Overall average claim sizes

The chart below shows the average claim size for non-nil, non-large claims inflated to mid 2017/18 money terms.

As discussed earlier in this report, our previous valuation had a single average claim size assumption for all age groups (being $364,000 in mid 2017/18 money terms). However, at this valuation, we have derived separate assumptions for four age groups.

Figure 7.1: Average attritional awards (inflated to mid 2017/18 money terms) and number of non-nil claims settlements for mesothelioma claims (excluding large claims)

The chart shows the historical variability in average claim sizes for mesothelioma, i.e. from $285,000 to $380,000 in mid 2017/18 money terms.

The experience in 2017/18 was 17% below expectations.

It is worth noting the variation between the cost of direct claims and cross claims and also the variation in claim sizes based on the number of defendants in a “direct claim”. 
It can be seen from the above charts that average mesothelioma claim sizes payable by the Liable Entities have fallen in the last three years for multi-defendant cases (where the Liable Entities are on average paying around 60% of the total amount awarded to the claimant).

A similar trend has been observed over the last five years for single-defendant cases (where the Liable Entities pay 100% of the award).

The claims experience for single-defendant claims in 2016/17 appeared to be unusually low. The claims experience in 2017/18 appears to have reverted to previous norms.
7.2.2 Claim sizes by age of claimant

The following chart shows that there is a significant difference between the average costs of claims for different age groups.

Figure 7.4: Average attritional awards (inflated to mid 2017/18 money terms) by age of claimant

The key factor that has led to claim sizes reducing (as shown in Figure 7.1) has been the increasing proportion of claims that have emerged from claimants over the age of 80 and the reduction in the proportion of claims emerging from claimants under the age of 60.

The sharp fall in overall average claim sizes in 2016/17 appears to be primarily a result of fewer claims over $500,000; claims of this size primarily come from claimants under the age of 70 years old.

Given the smaller number of claims involved in relation to claimants under the age of 70, it is possible that the 2016/17 experience was more a function of random variability and specific characteristics relating to the small number of claimants. As such, we have not given significant credibility to the 2016/17 experience in setting the valuation assumptions at this valuation.
7.2.3 Claim size assumptions by age of claimant

For claimants under the age of 60:

- The last three years have averaged $534,000; the last four years have averaged $563,000; the last five years have averaged $605,000.
- The three-year and four-year averages are particularly impacted by the favourable experience in 2016/17.
- The average size for 2017/18 was $590,000.
- We have taken a longer-term view noting the smaller numbers of claims in this age group and because it currently appears that 2016/17 was unusually low.
- We have therefore selected an assumption of $600,000.

For claimants aged 60-70:

- The last three years have averaged $360,000; the last four years have averaged $370,000; the last five years have averaged $373,000.
- The most recent two years have been particularly favourable relative to the preceding seven years and it is currently unclear why this is the case.
- The average size for 2017/18 was $339,000.
- We have taken a longer-term view noting the smaller numbers of claims in this age group and because it is currently unclear what has given rise to the favourable experience in 2016/17 and 2017/18.
- We have therefore selected an assumption of $375,000.

For claimants aged 70-80:

- The last three years have averaged $281,000; the last four years have averaged $280,000; the last five years have averaged $285,000.
- The average size for 2017/18 was $285,000.
- We have therefore selected an assumption of $285,000.

For claimants aged 80+:

- The last three years have averaged $229,000; the last four years have averaged $235,000; the last five years have averaged $237,000.
- The average size for 2017/18 was $210,000. It is currently unclear what has given rise to this materially favourable experience.
- We have therefore selected an assumption of $235,000.
7.3 **Asbestosis claims**

For asbestosis, it can be seen from Table 7.1 that the period since 2007/08 has had volatile average claim size experience, with average claim sizes ranging from $82,000 to $149,000 (in mid 2017/18 money terms).

Figure 7.5: Average awards (inflated to mid 2017/18 money terms) and number of non-nil claims settlements for asbestosis claims

The average of the past three years is $99,000; the average of the past four years is $103,000 and the average of the past five years is $105,000.

In setting an assumption, we also note there has been one asbestosis claim settled for more than $1.6m in 2016/17 money terms (i.e. it is a “large claim” and is not shown in the above analysis).

Taking all of the above factors into consideration, we have adopted a valuation assumption of $105,000 for asbestosis claims in mid 2017/18 money terms. This assumption represents an 11% decrease in inflation-adjusted terms.

Table 7.2: Average asbestosis claims assumptions

<table>
<thead>
<tr>
<th>Valuation Report</th>
<th>Claim settlement year 2016/17</th>
<th>2017/18</th>
</tr>
</thead>
<tbody>
<tr>
<td>31-Mar-17</td>
<td>112,000</td>
<td>118,200</td>
</tr>
<tr>
<td>31-Mar-18</td>
<td>n/a</td>
<td>105,000</td>
</tr>
</tbody>
</table>

*Note: 2016/17 settlements are in 2016/17 dollars whilst 2017/18 settlements are in 2017/18 dollars.*
7.4 Lung cancer claims

The average award for lung cancer claims has exhibited some volatility in the past five years, although this is not unexpected given the small volume of claim settlements (approximately 10 to 30 claims per annum).

Figure 7.6: Average awards (inflated to mid 2017/18 money terms) and number of non-nil claims settlements for lung cancer claims

The average of the past three years is $98,000; the average of the past four years is $119,000 and the average of the past five years is $120,000.

Taking all of the above factors into consideration, we have adopted a valuation assumption of $120,000. This assumption represents a decrease of 9% in inflation-adjusted terms from our previous assumption.

Table 7.3: Average lung cancer claims assumptions

<table>
<thead>
<tr>
<th>Valuation Report</th>
<th>Claim settlement year</th>
<th>2016/17</th>
<th>2017/18</th>
</tr>
</thead>
<tbody>
<tr>
<td>31-Mar-17</td>
<td>125,000</td>
<td>131,900</td>
<td></td>
</tr>
<tr>
<td>31-Mar-18</td>
<td>n/a</td>
<td>120,000</td>
<td></td>
</tr>
</tbody>
</table>

Note: 2016/17 settlements are in 2016/17 dollars whilst 2017/18 settlements are in 2017/18 dollars.
7.5 ARPD & Other claims

The average award size has shown considerable volatility and three of the last four years have seen some of the lowest average claim sizes historically observed.

Figure 7.7: Average awards (inflated to mid 2017/18 money terms) and number of non-nil claims settlements for ARPD & Other claims

For ARPD & Other claims, the average of the past three years is $88,000; the average of the past four years is $86,000 and the average of the past five years is $92,000.

Taking all of the above factors into consideration, we have adopted a valuation assumption of $95,000 for ARPD & Other claims in mid 2017/18 money terms. This assumption represents a decrease of 10% in inflation-adjusted terms from our previous assumption.

Table 7.4: Average ARPD & Other claims assumptions

<table>
<thead>
<tr>
<th>Valuation Report</th>
<th>Claim settlement year</th>
<th>2016/17</th>
<th>2017/18</th>
</tr>
</thead>
<tbody>
<tr>
<td>31-Mar-17</td>
<td>100,000</td>
<td>105,500</td>
<td></td>
</tr>
<tr>
<td>31-Mar-18</td>
<td>n/a</td>
<td>95,000</td>
<td></td>
</tr>
</tbody>
</table>

*Note: 2016/17 settlements are in 2016/17 dollars whilst 2017/18 settlements are in 2017/18 dollars.*
### 7.6 Workers Compensation claims

The average award for non-nil Workers Compensation claims has shown a large degree of volatility, reflecting the small number of non-nil claims.

**Figure 7.8: Average awards (inflated to mid 2017/18 money terms) and number of non-nil claims settlements for Workers Compensation claims**

It should be noted that the high average claim size in 2011/12 is due to one claim of $900,000 (in 2011/12 values). Furthermore, we understand that this claim payment was able to be recovered from the workers compensation insurer at a later date.

At this valuation, we have adopted an average award size of $137,000. This represents no material change in inflation-adjusted terms from our previous assumption.

This assumption is not material to the overall liability given the high proportion of claims (in excess of 90%) which are settled with no retained liability against the Liable Entities.

**Table 7.5: Average Workers Compensation claims assumptions**

<table>
<thead>
<tr>
<th>Valuation Report</th>
<th>Claim settlement year</th>
<th>2016/17</th>
<th>2017/18</th>
</tr>
</thead>
<tbody>
<tr>
<td>31-Mar-17</td>
<td></td>
<td>130,000</td>
<td>137,200</td>
</tr>
<tr>
<td>31-Mar-18</td>
<td></td>
<td>n/a</td>
<td>137,000</td>
</tr>
</tbody>
</table>

*Note: 2016/17 settlements are in 2016/17 dollars whilst 2017/18 settlements are in 2017/18 dollars.*
7.7 Wharf claims

For wharf claims, the average of the past three years has been $91,000; the average of the past four years has been $91,000 and the average of the past five years has been $96,000.

Figure 7.9: Average awards (inflated to mid 2017/18 money terms) and number of non-nil claims settlements for wharf claims

The experience in 2008/09 was impacted by one large claim of almost $600,000 (in 2008/09 values).

At this valuation, we have adopted a valuation assumption of $100,000 in mid 2017/18 money terms. This assumption represents a 14% decrease compared to our previous valuation in inflation-adjusted terms.

Given the small volume of wharf claims, this assumption is not financially significant to the overall results.

Table 7.6: Average wharf claims assumptions

<table>
<thead>
<tr>
<th>Valuation Report</th>
<th>Claim settlement year</th>
<th>2016/17</th>
<th>2017/18</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mar-17 Valn</td>
<td>110,000</td>
<td>116,100</td>
<td></td>
</tr>
<tr>
<td>Mar-18 Valn</td>
<td>n/a</td>
<td>100,000</td>
<td></td>
</tr>
</tbody>
</table>

Note: 2016/17 settlements are in 2016/17 dollars whilst 2017/18 settlements are in 2017/18 dollars.
7.8 Mesothelioma large claim size and incidence rates

There have been 66 mesothelioma claims settled with awards in excess of $1m in 2006/07 money terms. All of these claims are product and public liability claims.

In aggregate these claims have been settled at an average cost of approximately $2.29m. There have been two claims of more than $5.0m each in mid 2017/18 money terms.

In selecting a large claim incidence rate, or expected annual number of large claims, we have analysed the number of large claims by year of notification, separately for each of the four age groups.

We have also shown the incidence rate of large claims for each of the age groups.

**Figure 7.10: Number of large claims by year of notification**

There have been no large claims for claimants over the age of 80.

**Figure 7.11: Large claims incidence rate by age of claimant**

There have been no large claims for claimants over the age of 80.
We have assumed a future large claim incidence rate of 9.00% for claimants under 60 years of age, 1.00% for claimants between 60 and 70 years of age, and 0.10% for claimants between 70 and 80 years of age. These assumptions produce an overall number of large claims of 4 claims assumed for 2018/19.

For the average large claim size, we have adopted a valuation assumption of $2.23m in mid 2017/18 money terms and we have adopted the same average claim size for all age groups. This is based on analysis that shows minimal variation between claimants under 60 and those between 60 and 70 years of age; noting the small number of large claims in the 60-70 age group.

In relation to legal costs, we have made an additional allowance for plaintiff legal costs to allow for those instances where such costs are made additional to, rather than included with, the claims award and also for defence costs.

The actual incidence of, and settlement of, large claims is not readily predictable and therefore deviations will occur from year to year due to random fluctuations because of the small numbers of large claims (between 1 and 8 large claims per annum).

For other disease types, we observe that there has been (in 2014/15) one asbestosis claim which exceeds the “large claims threshold”. We have made implicit allowance for this claim in setting our attritional claim size assumption for that disease type.

7.9 Summary average claim cost assumptions

The following table provides a summary of our average claim cost assumptions at this valuation, and those assumed at the previous valuation.

Table 7.7: Summary average claim cost assumptions

<table>
<thead>
<tr>
<th></th>
<th>Current Valuation</th>
<th>Previous Valuation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mesothelioma: &lt;60</td>
<td>600,000</td>
<td>364,000</td>
</tr>
<tr>
<td>Mesothelioma: 60-70</td>
<td>375,000</td>
<td></td>
</tr>
<tr>
<td>Mesothelioma: 70-80</td>
<td>285,000</td>
<td></td>
</tr>
<tr>
<td>Mesothelioma: 80+</td>
<td>235,000</td>
<td></td>
</tr>
<tr>
<td>Asbestosis</td>
<td>105,000</td>
<td>118,200</td>
</tr>
<tr>
<td>Lung Cancer</td>
<td>120,000</td>
<td>131,900</td>
</tr>
<tr>
<td>ARPD &amp; Other</td>
<td>95,000</td>
<td>105,500</td>
</tr>
<tr>
<td>Wharf</td>
<td>100,000</td>
<td>116,100</td>
</tr>
<tr>
<td>Workers Compensation</td>
<td>137,000</td>
<td>137,200</td>
</tr>
</tbody>
</table>

| Mesothelioma Large Claims (award only) | Average Size: $2.23m. Frequency: 9.00% (<60), 1.00% (60-70), 0.1% (70-80) | Average Size: $2.332m. Frequency: 1.50% |

Note: Both the current valuation assumption and the previous valuation assumption are expressed in mid 2017/18 money terms.
7.10 Defence legal costs

7.10.1 Non-nil claims

The average defence legal costs for non-nil claims by settlement year have been relatively stable over the last ten years for mesothelioma, asbestosis and ARPD & Other.

The average defence costs for lung cancer have shown a greater degree of variability, although this is not unexpected given the small volume of claim settlements (approximately 10 to 30 claims per annum).

Figure 7.12: Average defence legal costs (inflated to mid 2017/18 money terms) for non-nil claims settlements by settlement year

Note: The chart does not include average defence costs for Wharf and Worker claims due to the smaller number of claims involved and the variability that exists as a consequence.

7.10.2 Large claims

The average defence legal costs across all 66 large claims has been $157,000 although this has generally been trending downwards over time.

We have allowed for defence legal costs of $100,000 per large claim having regard to more recent experience.

7.10.3 Nil claims

The average defence legal costs for nil claims by settlement year has been volatile for all disease types.

For mesothelioma, the volatility is a consequence of low nil settlement rate, meaning that there may be 20 to 30 nil claims in any year.

For the other disease types, the number of nil claims might typically be of the order of 10 claims per annum for each disease type.
7.11 Summary average defendant legal costs assumptions

The following table provides a summary of our defendant legal costs assumptions at this valuation, and those assumed at the previous valuation.

We have adopted different legal cost assumptions for mesothelioma for the four age groups, based on analysis which indicates there is variation (which in part will be related to the average size of claims in each age group).

Table 7.8: Summary average defendant legal costs assumptions

<table>
<thead>
<tr>
<th></th>
<th>Current Valuation Non Nil Claims</th>
<th>Current Valuation Nil Claims</th>
<th>Previous Valuation Non Nil Claims</th>
<th>Previous Valuation Nil Claims</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mesothelioma: &lt;60</td>
<td>32,000</td>
<td>30,000</td>
<td>18,600</td>
<td>18,600</td>
</tr>
<tr>
<td>Mesothelioma: 60-70</td>
<td>22,000</td>
<td>11,000</td>
<td>25,900</td>
<td>8,800</td>
</tr>
<tr>
<td>Mesothelioma: 70-80</td>
<td>19,000</td>
<td>11,000</td>
<td>20,700</td>
<td>12,900</td>
</tr>
<tr>
<td>Mesothelioma: 80+</td>
<td>17,000</td>
<td>11,000</td>
<td>16,000</td>
<td>1,600</td>
</tr>
<tr>
<td>Asbestos</td>
<td>17,500</td>
<td>9,000</td>
<td>18,100</td>
<td>10,400</td>
</tr>
<tr>
<td>Lung Cancer</td>
<td>25,000</td>
<td>15,000</td>
<td>25,900</td>
<td>8,800</td>
</tr>
<tr>
<td>ARPD &amp; Other</td>
<td>18,000</td>
<td>8,000</td>
<td>20,700</td>
<td>12,900</td>
</tr>
<tr>
<td>Wharf</td>
<td>15,000</td>
<td>5,000</td>
<td>20,700</td>
<td>2,600</td>
</tr>
<tr>
<td>Workers Compensation</td>
<td>15,000</td>
<td>1,000</td>
<td>16,000</td>
<td>1,600</td>
</tr>
<tr>
<td>Mesothelioma Large</td>
<td>100,000</td>
<td></td>
<td>96,300</td>
<td></td>
</tr>
</tbody>
</table>

Note: Both the current valuation assumption and the previous valuation assumption are expressed in mid 2017/18 money terms.
## 8. Claims Experience: Nil Settlement Rates

### 8.1 Overview

We have analysed the nil settlement rates, being the number of nil settlements expressed as a percentage of the total number of settlements (nil and non-nil).

The table below shows the observed nil settlement rates by disease type and by settlement year.

**Table 8.1: Nil settlement rates**

<table>
<thead>
<tr>
<th>Client Settlement Year</th>
<th>Mesothelioma</th>
<th>Asbestosis</th>
<th>Lung Cancer</th>
<th>ARPD &amp; Other</th>
<th>Wharf Compensation</th>
</tr>
</thead>
<tbody>
<tr>
<td>2007</td>
<td>13%</td>
<td>9%</td>
<td>31%</td>
<td>19%</td>
<td>72%</td>
</tr>
<tr>
<td>2008</td>
<td>8%</td>
<td>9%</td>
<td>24%</td>
<td>13%</td>
<td>0%</td>
</tr>
<tr>
<td>2009</td>
<td>8%</td>
<td>8%</td>
<td>29%</td>
<td>2%</td>
<td>14%</td>
</tr>
<tr>
<td>2010</td>
<td>6%</td>
<td>6%</td>
<td>41%</td>
<td>14%</td>
<td>0%</td>
</tr>
<tr>
<td>2011</td>
<td>10%</td>
<td>7%</td>
<td>32%</td>
<td>11%</td>
<td>0%</td>
</tr>
<tr>
<td>2012</td>
<td>9%</td>
<td>16%</td>
<td>23%</td>
<td>20%</td>
<td>40%</td>
</tr>
<tr>
<td>2013</td>
<td>3%</td>
<td>8%</td>
<td>3%</td>
<td>13%</td>
<td>20%</td>
</tr>
<tr>
<td>2014</td>
<td>9%</td>
<td>11%</td>
<td>12%</td>
<td>8%</td>
<td>9%</td>
</tr>
<tr>
<td>2015</td>
<td>7%</td>
<td>6%</td>
<td>25%</td>
<td>8%</td>
<td>8%</td>
</tr>
<tr>
<td>2016</td>
<td>20%</td>
<td>13%</td>
<td>58%</td>
<td>16%</td>
<td>9%</td>
</tr>
<tr>
<td>2017</td>
<td>8%</td>
<td>18%</td>
<td>59%</td>
<td>7%</td>
<td>9%</td>
</tr>
</tbody>
</table>
8.2 Mesothelioma claims

The following chart shows the number of claims settled for nil cost, the total number of claims settled and the implied nil settlement rate for each settlement year.

Figure 8.1: Mesothelioma nil claims experience

In considering the future nil settlement rate assumption, we note the following:

- The nil settlement rate for the past three years has averaged 11%, for the past four years has averaged 11% and for the past five years has averaged 9%. Each of these is significantly impacted by the 20% rate observed in 2016/17.
- The nil settlement rate for the 2016/17 year of 20% was due to 54 Queensland statutory recovery claims being closed at nil cost in December 2016.
- Excluding the 54 Queensland Statutory nil claims, the nil settlement rate for 2016/17 was 7.9%.
- The nil settlement rate for 2017/18 was 7.7% compared to our assumption of 7.0%.

Taking all of these factors into consideration, we have assumed a future nil settlement rate of 7.0%, unchanged from our previous valuation.

We have applied this assumption to all age groups. We have done this because analysis by age group did not seem to indicate materially different nil settlement rates for the four age groups over time, and because the number of nil claims annually (typically around 25 across all ages) is quite small, meaning that sub-division of experience into four age groups results in reduced credibility and greater volatility.
8.3 Asbestosis claims

As with mesothelioma, the historical asbestosis nil settlement rate has been volatile.

Figure 8.2: Asbestosis nil claims experience

In considering the future nil settlement rate assumption, we note the following:

- The nil settlement rate for the past three years has averaged 12%, for the past four years has averaged 12% and for the past five years has averaged 11%.

- The nil settlement rate for 2016/17 was 13%. Excluding 2 Queensland Statutory nil claims, the nil settlement rate was 11%.

- The nil settlement rate for 2017/18 was 18%.

Taking all of these factors into consideration, we have assumed a future nil settlement rate of 11.0%, an increase from our previous valuation assumption of 9.0%.
8.4 Lung cancer claims

Given the small volumes of claims, volatility in the nil settlement rate for lung cancer claims is to be expected.

Figure 8.3: Lung cancer nil claims experience

In considering the future nil settlement rate assumption, we note the following:

- The nil settlement rate for the past three years has averaged 48%, for the past four years has averaged 37% and for the past five years has averaged 28%.

- The nil settlement rate for 2017/18 was 59%, the highest nil settlement rate observed historically, and this compares with our assumption (at 31 March 2017) of 23%.

Taking all of these factors into consideration, we have assumed a future nil settlement rate of 25%, an increase from our previous assumption of 23%.
8.5 ARPD & Other claims

As with other disease types, there has been significant volatility in the historical nil settlement rate, given the low numbers of claims for this disease.

Figure 8.4: ARPD & Other nil claims experience

The nil settlement rate for the past three years has averaged 10%, for the past four years has averaged 10% and for the past five years has averaged 10%.

We have selected 10% as our nil settlement rate assumption, a decrease from our previous assumption of 13%.
8.6 Workers Compensation claims

The nil settlement rates for Workers Compensation claims have been high and reflect the portion of claims whose costs are fully met by a Workers Compensation Scheme or Policy. The proportion of such claims which are fully met by insurance has been relatively stable since 1997/98, typically varying between 80% and 100%.

The nil settlement rate has been in excess of 90% for seven of the past ten years, and it has been above 80% for nine out of the past ten years.

Figure 8.5: Workers Compensation nil claims experience

![Graph showing nil settlement rate and number of claims over years]

We have selected 97% as our nil settlement rate assumption, unchanged from our previous valuation.

The overall financial impact of this assumption is not material.
8.7 Wharf claims

During the past eight years, the nil settlement rate has exhibited considerably volatility for wharf claims, varying between 0% and 40%.

The nil settlement rate for the past three years has averaged 9%, for the past four years it has averaged 9% and for the past five years it has averaged 11%.

Figure 8.6: Wharf nil claims experience

We have selected a nil settlement rate assumption of 10%, a decrease from our previous valuation assumption of 15%.

Given the low volume of claims activity for wharf claims, this assumption is highly subjective but is also not material to the overall liability assessment.

8.8 Summary assumptions

The following table provides a summary of our nil settlement rate assumptions at this valuation, and those assumed at the previous valuation.

Table 8.2: Summary nil settlement rate assumptions

<table>
<thead>
<tr>
<th></th>
<th>Current Valuation</th>
<th>Previous Valuation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mesothelioma</td>
<td>7.0%</td>
<td>7.0%</td>
</tr>
<tr>
<td>Asbestosis</td>
<td>11.0%</td>
<td>9.0%</td>
</tr>
<tr>
<td>Lung Cancer</td>
<td>25.0%</td>
<td>23.0%</td>
</tr>
<tr>
<td>ARPD &amp; Other</td>
<td>10.0%</td>
<td>13.0%</td>
</tr>
<tr>
<td>Wharf</td>
<td>10.0%</td>
<td>15.0%</td>
</tr>
<tr>
<td>Workers Compensation</td>
<td>97.0%</td>
<td>97.0%</td>
</tr>
</tbody>
</table>
9. Economic and Other Assumptions

9.1 Overview

The two main economic assumptions required for our valuation are:

- The underlying claims inflation assumptions adopted to project the future claims settlement amounts and related costs.
- The discount rate adopted for the present value determinations.

We also discuss the basis of derivation of other valuation assumptions, being:

- The cross-claim recovery rate; and
- The pattern of settlement of future reported claims and pending claims.

9.2 Claims inflation

We are required to make assumptions about the future rate of inflation of claims costs.

We have adopted a standard Australian actuarial claims inflation model for liabilities of the type considered in this report that is based on:

- An underlying, or base, rate of general economic inflation relevant to the liabilities, in this case based on wage/salary (earnings) inflation; and
- A rate of superimposed inflation, i.e. the rate at which claims costs inflation exceeds base inflation.

9.2.1 Base inflation

We have adopted a long-term base (wage) inflation assumption of 4.00% per annum. This is unchanged from the previous valuation assumption.

With the current prevailing economic conditions, including lower yields and implied lower outlook for inflation measures, we consider it appropriate to select lower short term assumptions for base inflation.

In the short to medium term, we have adopted 3.75% as the base assumption for 2018/19 and 4.00% for 2019/20. We have assumed that the long-term rates of base inflation (4.00% per annum) will apply from 2020/21 onwards.

The following table summarizes the base inflation assumptions we have selected for the current and previous valuations.
Table 9.1: Base inflation assumptions

<table>
<thead>
<tr>
<th></th>
<th>Current Valuation</th>
<th>Previous Valuation</th>
</tr>
</thead>
<tbody>
<tr>
<td>2017/18</td>
<td>n/a</td>
<td>3.50%</td>
</tr>
<tr>
<td>2018/19</td>
<td>3.75%</td>
<td>3.75%</td>
</tr>
<tr>
<td>2019/20</td>
<td>4.00%</td>
<td>4.00%</td>
</tr>
<tr>
<td>Long-term</td>
<td>4.00%</td>
<td>4.00%</td>
</tr>
</tbody>
</table>

These assumptions apply both to claims awards and legal costs.

9.2.2 Superimposed inflation

Superimposed inflation is a term commonly used by Australian actuaries to measure the rate at which average claims costs escalate in excess of a base (usually wage) inflation measure. As a result, superimposed inflation is a “catch-all” for a range of potential factors affecting claims costs, including (but not limited to):

- Courts making compensation payments in relation to new heads of damage;
- Courts changing the levels of compensation paid for existing heads of damage;
- Advancements in medical treatments – for example, this could lead to higher medical treatment costs (e.g. the cost of the use of new drug treatments);
- Allowance for medical costs to rise faster than wages because of the use of enhanced medical technologies;
- Changes in life expectancy;
- Changes in retirement age – this would have the potential to increase future economic loss awards;
- Changes in the relative share of the liability to be borne by the Liable Entities’ (which we refer to as “the contribution rate”) and which might result from changes in the number of defendants joined in claims;
- Changes in the mix of claims costs by different heads of damage; and
- Changes in the mix of claimants by age of claimant.

Additionally, superimposed inflation also captures those characteristics of claims experience which might have different relative claim sizes but which are currently modelled in aggregate (rather than explicitly and separately modelled). This includes factors such as:

- Changes in the mix of claims between direct and cross claims;
- Changes in the mix of claims between renovator and non-renovator claims; and
- Changes in the mix of claims by the numbers of defendants to each claim.

Whilst the future rate of superimposed inflation is uncertain, and not predictable from one year to the next, it is of note that the average claim costs appear to have been relatively stable in recent years (after adjusting for wage inflation) and that, if anything, average claim sizes
have trended downwards in recent years. As discussed elsewhere in this report, this reflects the changing mix of claimants by claimant age (shifting towards older claimants).

Furthermore, the emergence of new or expanding heads of damage does not tend to proceed smoothly but progresses in “steps”, depending on the outcome of legislative and other developments.

We have reviewed the rate of inflation of claims costs by settlement year for the past 18 years for mesothelioma claims. We have assessed this by analysing inflated claim costs and therefore the following chart measures the trend in the rate of superimposed inflation.

We have separately considered each of the four age groups to detect whether superimposed inflation is emerging in some or all of the age groups.

**Figure 9.1: Average mesothelioma awards of the Liable Entities (inflated to mid 2017/18 money terms) by age of claimant**

For claimants under 60 years of age, the rate of superimposed inflation:

- Averaged (0.2)% per annum for 2000/01 to 2017/18;
- Averaged (0.8)% per annum for 2002/03 to 2017/18;
- Averaged 1.2% per annum for 2004/05 to 2017/18;
- Averaged 0.1% per annum for 2007/08 to 2017/18.

For claimants 60-70 years of age, the rate of superimposed inflation:

- Averaged (0.7)% per annum for 2000/01 to 2017/18;
- Averaged (1.6)% per annum for 2002/03 to 2017/18;
- Averaged 0.4% per annum for 2004/05 to 2017/18;
- Averaged 0.2% per annum for 2007/08 to 2017/18.
For claimants 70-80 years of age, the rate of superimposed inflation:

- Averaged 0.1% per annum for 2000/01 to 2017/18;
- Averaged (0.8)% per annum for 2002/03 to 2017/18;
- Averaged 0.2% per annum for 2004/05 to 2017/18;
- Averaged 0.9% per annum for 2007/08 to 2017/18.

For claimants 80+ years of age, the rate of superimposed inflation:

- Averaged 1.0% per annum for 2000/01 to 2017/18;
- Averaged (2.5)% per annum for 2002/03 to 2017/18;
- Averaged (1.3)% per annum for 2004/05 to 2017/18;
- Averaged (0.3)% per annum for 2007/08 to 2017/18.

The actuarial approach for this report is to take an average view for superimposed inflation to be applied over the long-term, noting that there will necessarily be deviations from this average on an annual basis and that cashflows are projected for the next 50 or more years.

Weighing all of the evidence together, and in particular recognising that the period since 2000/01 has generally been benign, we have adopted an assumed long-term rate of future superimposed inflation of claims awards of 2.00% per annum.

This assumption is applied to the claim awards for each of the four age groups for mesothelioma and is also applied to the claim awards for other disease types.

There is no superimposed inflation applied to legal costs.

The assumption for superimposed inflation is unchanged from the previous valuation.

The outcome of this assumption is a “superimposed inflation allowance” of approximately $250m on a discounted central estimate basis and approximately $380m on an inflated and undiscounted central estimate basis.
9.3 Discount rates: Commonwealth bond zero coupon yields

We have calculated the zero coupon yield curve at 31 March 2018 underlying the prices, coupons and durations of Commonwealth Government Bonds for the purpose of discounting the liabilities for this report.

The use of such discount rates is consistent with standard Australian actuarial practice for such liabilities, is in accordance with the Institute of Actuaries of Australia’s Professional Standard PS300 and is also consistent with our understanding of the Australian accounting standards.

The chart below shows the assumptions for the current valuation and the previous valuation.

Figure 9.2: Zero coupon yield curve by duration

We observe that the long-term discount rate assumption that we have adopted (5.50% per annum) does not materially affect the overall Discounted Central Estimate. This is because the vast majority of the future cashflows (more than 85%) are projected to be paid over the next 18 years.

By way of illustration, if we selected a long-term discount rate of 5.00% per annum, the Discounted Central Estimate would increase by approximately $4m (0.2%).

The long-term discount rate we have selected (5.50% per annum) has been set to be broadly consistent with our selected long-term wage inflation assumption (4.00% per annum).
9.4 Cross-claim recovery rates

The following chart shows how the experience of cross-claim recoveries has varied over the last seven years, both in monetary terms and expressed as a percentage of gross payments.

**Figure 9.3: Cross-claim recovery experience**

Cross claim recoveries reduced year on year from 2012/13 to 2015/16, both in absolute terms and as a percentage of gross payments. In 2016/17, there was a material increase in the level of cross-claim recoveries. There was a further increase in 2017/18.

Over the seven-year period, cross claim recoveries have been approximately 3.0% of claims awards.

In light of the additional year of experience, we have now increased our assumption for cross-claim recoveries to be 2.5% of claims awards (31 March 2017: 1.5%).
9.5 Settlement Patterns

Triangulation methods are used to derive the past pattern of settlement of claims and are used in forming a view on future settlement patterns.

The following triangles provide an illustrative example of how we perform this:

Figure 9.4: Settlement pattern derivation for mesothelioma claims: paid as % of ultimate cost

<table>
<thead>
<tr>
<th>Settlement</th>
<th>12</th>
<th>24</th>
<th>36</th>
<th>48</th>
<th>60</th>
<th>84</th>
<th>126</th>
<th>189</th>
<th>252</th>
<th>336</th>
<th>429</th>
</tr>
</thead>
<tbody>
<tr>
<td>2020</td>
<td>58.2</td>
<td>83.4</td>
<td>95.4</td>
<td>98.1</td>
<td>98.8</td>
<td>100.0</td>
<td>100.0</td>
<td>100.0</td>
<td>100.0</td>
<td>100.0</td>
<td>100.0</td>
</tr>
<tr>
<td>2021</td>
<td>58.1</td>
<td>83.1</td>
<td>95.1</td>
<td>98.0</td>
<td>98.8</td>
<td>100.0</td>
<td>100.0</td>
<td>100.0</td>
<td>100.0</td>
<td>100.0</td>
<td>100.0</td>
</tr>
<tr>
<td>2022</td>
<td>57.8</td>
<td>83.0</td>
<td>95.1</td>
<td>97.9</td>
<td>98.8</td>
<td>100.0</td>
<td>100.0</td>
<td>100.0</td>
<td>100.0</td>
<td>100.0</td>
<td>100.0</td>
</tr>
<tr>
<td>2023</td>
<td>57.6</td>
<td>82.9</td>
<td>95.0</td>
<td>97.7</td>
<td>98.8</td>
<td>99.9</td>
<td>100.0</td>
<td>100.0</td>
<td>100.0</td>
<td>100.0</td>
<td>100.0</td>
</tr>
<tr>
<td>2024</td>
<td>57.4</td>
<td>82.8</td>
<td>95.0</td>
<td>97.6</td>
<td>98.8</td>
<td>99.9</td>
<td>99.9</td>
<td>100.0</td>
<td>100.0</td>
<td>100.0</td>
<td>100.0</td>
</tr>
<tr>
<td>2025</td>
<td>57.3</td>
<td>82.8</td>
<td>94.9</td>
<td>97.6</td>
<td>98.8</td>
<td>99.9</td>
<td>99.9</td>
<td>99.9</td>
<td>100.0</td>
<td>100.0</td>
<td>100.0</td>
</tr>
<tr>
<td>2026</td>
<td>57.2</td>
<td>82.7</td>
<td>94.9</td>
<td>97.6</td>
<td>98.8</td>
<td>99.9</td>
<td>99.9</td>
<td>99.9</td>
<td>99.9</td>
<td>100.0</td>
<td>100.0</td>
</tr>
<tr>
<td>2027</td>
<td>57.1</td>
<td>82.7</td>
<td>94.9</td>
<td>97.6</td>
<td>98.8</td>
<td>99.9</td>
<td>99.9</td>
<td>99.9</td>
<td>99.9</td>
<td>99.9</td>
<td>100.0</td>
</tr>
</tbody>
</table>

Figure 9.5: Settlement pattern derivation for non-mesothelioma claims: paid as % of ultimate cost

<table>
<thead>
<tr>
<th>Settlement</th>
<th>12</th>
<th>24</th>
<th>36</th>
<th>48</th>
<th>60</th>
<th>84</th>
<th>126</th>
<th>189</th>
<th>252</th>
<th>336</th>
<th>429</th>
</tr>
</thead>
<tbody>
<tr>
<td>2020</td>
<td>58.2</td>
<td>83.6</td>
<td>95.6</td>
<td>98.4</td>
<td>98.8</td>
<td>100.0</td>
<td>100.0</td>
<td>100.0</td>
<td>100.0</td>
<td>100.0</td>
<td>100.0</td>
</tr>
<tr>
<td>2021</td>
<td>58.1</td>
<td>83.5</td>
<td>95.5</td>
<td>98.3</td>
<td>98.8</td>
<td>100.0</td>
<td>100.0</td>
<td>100.0</td>
<td>100.0</td>
<td>100.0</td>
<td>100.0</td>
</tr>
<tr>
<td>2022</td>
<td>57.9</td>
<td>83.3</td>
<td>95.4</td>
<td>98.3</td>
<td>98.8</td>
<td>100.0</td>
<td>100.0</td>
<td>100.0</td>
<td>100.0</td>
<td>100.0</td>
<td>100.0</td>
</tr>
<tr>
<td>2023</td>
<td>57.7</td>
<td>83.2</td>
<td>95.3</td>
<td>98.2</td>
<td>98.8</td>
<td>100.0</td>
<td>100.0</td>
<td>100.0</td>
<td>100.0</td>
<td>100.0</td>
<td>100.0</td>
</tr>
<tr>
<td>2024</td>
<td>57.6</td>
<td>83.1</td>
<td>95.2</td>
<td>98.2</td>
<td>98.8</td>
<td>99.9</td>
<td>100.0</td>
<td>100.0</td>
<td>100.0</td>
<td>100.0</td>
<td>100.0</td>
</tr>
<tr>
<td>2025</td>
<td>57.5</td>
<td>83.0</td>
<td>95.1</td>
<td>98.2</td>
<td>98.8</td>
<td>99.9</td>
<td>99.9</td>
<td>100.0</td>
<td>100.0</td>
<td>100.0</td>
<td>100.0</td>
</tr>
<tr>
<td>2026</td>
<td>57.4</td>
<td>82.9</td>
<td>95.1</td>
<td>98.2</td>
<td>98.8</td>
<td>99.9</td>
<td>99.9</td>
<td>99.9</td>
<td>100.0</td>
<td>100.0</td>
<td>100.0</td>
</tr>
<tr>
<td>2027</td>
<td>57.3</td>
<td>82.8</td>
<td>95.0</td>
<td>98.2</td>
<td>98.8</td>
<td>99.9</td>
<td>99.9</td>
<td>99.9</td>
<td>99.9</td>
<td>100.0</td>
<td>100.0</td>
</tr>
</tbody>
</table>

We have estimated the settlement pattern for future claim reporting as follows:

Table 9.2: Settlement pattern of claims awards by delay from claim reporting

<table>
<thead>
<tr>
<th>Delay (years)</th>
<th>Mesothelioma</th>
<th>Non-mesothelioma</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>60.0%</td>
<td>33.0%</td>
</tr>
<tr>
<td>1</td>
<td>35.0%</td>
<td>50.0%</td>
</tr>
<tr>
<td>2</td>
<td>3.0%</td>
<td>9.0%</td>
</tr>
<tr>
<td>3</td>
<td>1.0%</td>
<td>5.0%</td>
</tr>
<tr>
<td>4</td>
<td>0.5%</td>
<td>1.0%</td>
</tr>
<tr>
<td>5</td>
<td>0.3%</td>
<td>0.5%</td>
</tr>
<tr>
<td>6</td>
<td>0.2%</td>
<td>0.5%</td>
</tr>
<tr>
<td>7</td>
<td>0.0%</td>
<td>0.5%</td>
</tr>
<tr>
<td>8</td>
<td>0.0%</td>
<td>0.5%</td>
</tr>
<tr>
<td>9</td>
<td>0.0%</td>
<td>0.0%</td>
</tr>
</tbody>
</table>

These assumed settlements patterns have been modified slightly since our previous valuation, resulting in an assumption of a slight speeding-up for both mesothelioma claim and non-mesothelioma claim settlements.

For mesothelioma, we have adopted one pattern (for all four age groups) because analysis of the average time to settlement for each of the four age groups was not materially different to the overall average time to settlement aggregated across all age groups (there was less than one month’s variation).
10. Valuation Results

10.1 Central estimate liability

At 31 March 2018, our projected central estimate of the liabilities of the Liable Entities (the Discounted Central Estimate) to be met by the AICF Trust is $1,852.9m (March 2017: $1,740.1m).

We have not allowed for the future Operating Expenses of the AICF Trust or the Liable Entities in the liability assessment.

The following table shows a summary of our central estimate liability assessment and compares the current assessment with our previous valuation.

Table 10.1: Comparison of central estimate of liabilities

<table>
<thead>
<tr>
<th>31 March 2018</th>
<th>31 March 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$m</td>
</tr>
<tr>
<td>Gross of</td>
<td>Insurance</td>
</tr>
<tr>
<td>insurance</td>
<td>insurance</td>
</tr>
<tr>
<td>recoveries</td>
<td>recoveries</td>
</tr>
<tr>
<td>Total uninflated and undiscounted cash-flows</td>
<td>1,517.3</td>
</tr>
<tr>
<td>Inflation allowance</td>
<td>972.7</td>
</tr>
<tr>
<td>Total inflated and undiscounted cash-flows</td>
<td>2,490.0</td>
</tr>
<tr>
<td>Discounting allowance</td>
<td>(551.8)</td>
</tr>
<tr>
<td>Net present value liabilities</td>
<td>1,938.2</td>
</tr>
</tbody>
</table>
10.2 Comparison with previous valuation

In the absence of any change to the claim projection assumptions from our 31 March 2017 valuation, other than allowing for the changes in the discount rate, we would have projected a Discounted Central Estimate liability of $1,657.1m as at 31 March 2018.

This is a decrease of $83.0m relative to the valuation result at 31 March 2017, and this is due to:

- A reduction of $119.9m, being the net impact of expected claims payments (which reduce the liability) and the “unwind of discount” (to reflect the fact that cashflows are now one year nearer).
- An increase of $36.9m resulting from changes to the yield curve between 31 March 2017 and 31 March 2018.

Our liability assessment at 31 March 2018 of $1,852.9m represents an increase of $195.8m, which arises from changes to the actuarial assumptions. The increase is principally a consequence of:

- The revised modelling approach for mesothelioma which has allowed for higher numbers of claims after 2025 partially offset by reductions in average sizes by allowing for the impact of claimant age; and
- An increase to the base level of mesothelioma claims for 2018/19 and the consequential impact this has on the number of claims in all future years; offset by
- Removal of the allowance for Sullivan vs Gordon in Victoria (see Section 1.3.3 of this Report);
- Increased allowance for cross-claim recoveries; and
- Reductions for average claim sizes and defence legal costs for other disease types.
The following chart shows an analysis of the change in our liability assessments from 31 March 2017 to 31 March 2018 on a discounted basis.

**Figure 10.1: Analysis of change in central estimate liability (discounted basis)**

Note: Green bars signal that this factor has given rise to an increase in the liability whilst light blue bars signal that this factor has given rise to a reduction in the liability.
10.3 Comparison of valuation results since 30 September 2006

We have analysed how our valuation results have changed since the Initial Report (as defined in the Amended Final Funding Agreement) at 30 September 2006.

The table below shows the results over time.

We have used the inflated and undiscounted results as the comparison. We consider this to be the most appropriate assessment as it removes the impacts of changes in discount rates and the “unwind of the discount”.

Table 10.2: Comparison of valuation results since 30 September 2006

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Valuation result at end of previous financial year</td>
<td>3,169</td>
<td>2,811</td>
<td>3,027</td>
<td>3,124</td>
<td>2,906</td>
<td>2,661</td>
<td>2,525</td>
<td>2,513</td>
<td>2,805</td>
<td>2,743</td>
<td>2,427</td>
<td>2,200</td>
</tr>
<tr>
<td>Net payments made (actual)</td>
<td>-32</td>
<td>-95</td>
<td>-63</td>
<td>-46</td>
<td>-76</td>
<td>-76</td>
<td>-46</td>
<td>-46</td>
<td>-113</td>
<td>-121</td>
<td>-129</td>
<td>2</td>
</tr>
<tr>
<td>Expected valuation result (no actuarial changes)</td>
<td>3,137</td>
<td>2,796</td>
<td>2,934</td>
<td>3,038</td>
<td>2,830</td>
<td>2,630</td>
<td>2,439</td>
<td>2,400</td>
<td>2,684</td>
<td>2,614</td>
<td>2,429</td>
<td>2,076</td>
</tr>
<tr>
<td>Actual valuation at end of financial year</td>
<td>2,811</td>
<td>3,027</td>
<td>3,124</td>
<td>2,906</td>
<td>2,661</td>
<td>2,525</td>
<td>2,513</td>
<td>2,805</td>
<td>2,743</td>
<td>2,427</td>
<td>2,200</td>
<td>2,381</td>
</tr>
<tr>
<td>Impact of actuarial valuation changes</td>
<td>-326</td>
<td>271</td>
<td>196</td>
<td>-132</td>
<td>-169</td>
<td>-60</td>
<td>74</td>
<td>40</td>
<td>40</td>
<td>40</td>
<td>40</td>
<td>40</td>
</tr>
<tr>
<td>Cumulative changes since 30 September 2006</td>
<td>-326</td>
<td>-55</td>
<td>135</td>
<td>3</td>
<td>-166</td>
<td>-226</td>
<td>-152</td>
<td>253</td>
<td>312</td>
<td>125</td>
<td>-104</td>
<td>201</td>
</tr>
</tbody>
</table>

Note: For FY2007, the starting valuation ($3,169m) is the valuation at 30 September 2006, not the valuation at 31 March 2006.

The table shows that whilst there have been some years where there have been increases and some years where there have been decreases arising from changes to actuarial valuation assumptions, over the period from 30 September 2006 to 31 March 2018 the valuation has increased by approximately $200m (6% of the valuation contained in the Initial Report).

In terms of net cashflows, actual net payments of $989m have been made since 30 September 2006. This compares with an estimate of $1,203m projected for the same period (1 October 2006 to 31 March 2018) in the valuation at 30 September 2006.

After allowing for removal of the beneficial impact of HIH, Equitas and other commutations ($183m), actual net cashflows have been approximately $31m (2.6%) below those projected in the valuation at 30 September 2006.

Gross cashflows over the same period have been $32m (2.3%) below those projected in the valuation at 30 September 2006 ($1,364m vs $1,396m).
10.4  Cashflow projections

10.4.1  Historical cashflow expenditure

The following chart shows the historical expenditure by the Liable Entities relating to asbestos-related claim settlements since the formation of AICFL.

Figure 10.2: Historical claim-related expenditure of the Liable Entities

Gross cashflow payments in the 12 months to 31 March 2018 were $139.7m (FY17: $125.0m).

Gross cashflow was lower than expectations by $15m, primarily due to the lower average claim size of mesothelioma claims which were 17% below expectations, together with lower expenditure on large mesothelioma claims, which were $11m favourable to expectations, partially offset by higher numbers of claims settlements compared with expectations.

Actual net cashflow in 2017/18 was $23m lower than the net cashflow projected for 2017/18 ($146.7m) in our 31 March 2017 valuation report.
10.4.2 Key changes in cashflow projections by period of cashflow

The following table summarises how the projected cashflows compare between the current and previous valuation.

Table 10.3: Comparison of projected cashflows by period

<table>
<thead>
<tr>
<th>Figures in $m</th>
<th>Previous Valuation</th>
<th>Current Valuation</th>
<th>Valuation change</th>
<th>Valuation change (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>FY2018</td>
<td>147</td>
<td>124</td>
<td>-23</td>
<td>-16%</td>
</tr>
<tr>
<td>FY2019</td>
<td>164</td>
<td>143</td>
<td>-21</td>
<td>-13%</td>
</tr>
<tr>
<td>FY2020</td>
<td>164</td>
<td>158</td>
<td>-7</td>
<td>-4%</td>
</tr>
<tr>
<td>FY21 - FY25</td>
<td>720</td>
<td>743</td>
<td>23</td>
<td>3%</td>
</tr>
<tr>
<td>FY26 - FY30</td>
<td>490</td>
<td>586</td>
<td>96</td>
<td>20%</td>
</tr>
<tr>
<td>FY31 - FY40</td>
<td>421</td>
<td>590</td>
<td>168</td>
<td>40%</td>
</tr>
<tr>
<td>FY41 - FY45</td>
<td>61</td>
<td>102</td>
<td>41</td>
<td>67%</td>
</tr>
<tr>
<td>1 April 2045 onwards</td>
<td>33</td>
<td>59</td>
<td>27</td>
<td>81%</td>
</tr>
<tr>
<td>Total</td>
<td>2,200</td>
<td>2,505</td>
<td>305</td>
<td>14%</td>
</tr>
<tr>
<td>FY2018 to FY2025</td>
<td>1,194</td>
<td>1,167</td>
<td>-27</td>
<td>-2%</td>
</tr>
<tr>
<td>FY2026 onwards</td>
<td>1,005</td>
<td>1,337</td>
<td>332</td>
<td>33%</td>
</tr>
</tbody>
</table>

Note: Figures may not add “on sight” due to rounding.

It can be seen that the impact of the revised valuation modelling approach has most substantially impacted the period from 1 April 2025 and onwards. By way of illustration:

- Projected cashflows for the period 1 April 2017 to 31 March 2025 have decreased by $27m (2.5% of the previous valuation cashflows).
- Projected cashflows for the period from 1 April 2025 onwards have increased by $332m (33% of the previous valuation cashflows).

10.4.3 Future cashflow projections

The following chart shows the projected net cashflows underlying our current valuation and the projected net cashflow projection underlying our previous valuation at 31 March 2017.

Figure 10.3: Annual cashflow projections – inflated and undiscounted ($m)

Given the extremely long-tailed nature of asbestos-related liabilities, a small change in an individual assumption can have a significant impact upon the cashflow profile of the liabilities.
## 10.5 Amended Final Funding Agreement calculations

The Amended Final Funding Agreement sets out the basis on which payments will be made to the AICF Trust.

Additionally, there are a number of other figures specified within the Amended Final Funding Agreement that we are required to calculate. These are:

- Discounted Central Estimate;
- Term Central Estimate; and
- Period Actuarial Estimate.

### Table 10.4: Amended Final Funding Agreement calculations

<table>
<thead>
<tr>
<th>Description</th>
<th>$m</th>
</tr>
</thead>
<tbody>
<tr>
<td>Discounted Central Estimate (net of cross-claim recoveries, Insurance and Other Recoveries)</td>
<td>1,852.9</td>
</tr>
<tr>
<td>Period Actuarial Estimate (net of cross-claim recoveries, gross of Insurance and Other Recoveries) comprising:</td>
<td></td>
</tr>
<tr>
<td>Discounted value of cashflow in 2018/19</td>
<td>147.1</td>
</tr>
<tr>
<td>Discounted value of cashflow in 2019/20</td>
<td>159.4</td>
</tr>
<tr>
<td>Discounted value of cashflow in 2020/21</td>
<td>156.2</td>
</tr>
<tr>
<td>Term Central Estimate (net of cross-claim recoveries, Insurance and Other Recoveries)</td>
<td>1,835.5</td>
</tr>
</tbody>
</table>

The actual funding amount due at a particular date will depend upon a number of factors, including:

- the net asset position of the AICF Trust at that time;
- the free cash flow amount of the James Hardie Group in the preceding financial year; and
- the Period Actuarial Estimate in the latest Annual Actuarial Report.
**10.6 Insurance Recoveries**

Our liability valuation has made allowance for a discounted central estimate of Insurance Recoveries of $85.4m.

This estimate is comprised as follows:

Table 10.5: Insurance recoveries at 31 March 2018

<table>
<thead>
<tr>
<th>$m</th>
<th>Undiscounted central estimate</th>
<th>Discounted central estimate</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Gross liability</strong></td>
<td>2,490.0</td>
<td>1,938.2</td>
</tr>
<tr>
<td>Product liability recoveries</td>
<td>100.0</td>
<td>78.5</td>
</tr>
<tr>
<td> Bad and doubtful debt allowance (product)</td>
<td>(1.5)</td>
<td>(1.1)</td>
</tr>
<tr>
<td>Public liability recoveries</td>
<td>10.8</td>
<td>8.0</td>
</tr>
<tr>
<td> Bad and doubtful debt allowance (public)</td>
<td>(0.1)</td>
<td>(0.1)</td>
</tr>
<tr>
<td><strong>Insurance recovery asset</strong></td>
<td>109.1</td>
<td>85.4</td>
</tr>
<tr>
<td><strong>Net liability</strong></td>
<td>2,380.9</td>
<td>1,852.9</td>
</tr>
<tr>
<td>Insurance recovery rate</td>
<td>4.4%</td>
<td>4.5%</td>
</tr>
<tr>
<td>Bad and doubtful debt rate</td>
<td>1.5%</td>
<td>1.3%</td>
</tr>
<tr>
<td><strong>Value of Insurance Policies</strong></td>
<td><strong>Value of Insurance Policies</strong></td>
<td><strong>Value of Insurance Policies</strong></td>
</tr>
<tr>
<td>per Facility Agreement</td>
<td>77.5</td>
<td>77.5</td>
</tr>
</tbody>
</table>

The combined bad and doubtful debt rate is 1.3% on a discounted basis (2017: 2.5%).

The AICF Facility Agreement requires the Approved Actuary to calculate the discounted central estimate value of certain Insurance Policies, being those specified in Schedule 5 of the AICF Facility Agreement.

At 31 March 2018 the discounted central estimate of the Insurance Policies, as specified in Schedule 5 of the AICF Facility Agreement, is $77.5m (March 2017: $82.3m).
11. Uncertainty

11.1 Overview

There is uncertainty involved in any valuation of the liabilities of an insurance company or a self-insurer. The sources of such uncertainty include, but are not limited to:

- Parameter error – this is the risk that the parameters and assumptions chosen ultimately prove not to be reflective of future experience.
- Model error – this is the risk that the model selected for the valuation of the liabilities ultimately proves not to be adequate for the projection of the liabilities.
- Legal and social developments – this is the risk that the legal environment in which claims are settled changes relative to its current and historical position thereby causing significantly different awards.
- Future actual rates of inflation being different from that assumed.
- The general economic environment being different from that assumed.
- Potential sources of exposure – this is the risk that there exist sources of exposure which are as yet unknown or unquantifiable, or for which no liabilities have yet been observed, but which may trigger future claims.

In the case of asbestos liabilities, these uncertainties are exacerbated by the extremely long latency period from exposure to onset of disease and notification of a claim. Asbestos-related claims often take in excess of 40 years from original exposure to become notified and then settled, compared with an average delay from exposure to settlement of 4-5 years for many other compensation-type liabilities such as Comprehensive Third-Party injury liabilities or other Workers Compensation liabilities.

Specific forms of uncertainty relating to asbestos-related disease liabilities include:

- The difficulty in quantifying the extent and pattern of past asbestos exposures and the number and incidence of the ultimate number of lives that may be affected by asbestos related diseases arising from such past asbestos exposures;
- The timing of the peak level and future pattern of incidence of claims reporting for mesothelioma;
- The propensity of individuals affected by diseases arising from such exposure to file common law claims against defendants;
- The extent to which the Liable Entities will be joined in such future common law claims;
- The mix of claimants by age, in particular noting the shift towards older claimants and which has had a downwards effect on average claim sizes in recent years;
11.2 Sensitivity testing

As we have noted above, there are many sources of uncertainty. Actuaries often perform “sensitivity testing” to identify the impact of different assumptions on future experience, thereby providing an indication of the degree of parameter error risk to which the valuation assessment is exposed.

Sensitivity testing may be considered as being a mechanism for testing “what will the liabilities be if instead of choosing \[x\] for assumption \[a\] we choose \[y\]?“ It is also a mechanism for identifying how the result will change if experience turns out different in a particular way relative to that which underlies the central estimate expectations. As such, it provides an indication of the level of variability inherent in the valuation.

We have performed some sensitivity tests of the results of our central estimate valuation. We have sensitivity tested the following factors:

- **number of claims notified**: 10% above and below our central estimate assumption.
- **average claim cost of a non-nil claim**: 5% above and below our central estimate assumption.
- **nil settlement rate**: 2 percentage points above and below our central estimate assumption.
- **superimposed inflation**: being 0% per annum or 4% per annum over all future years.
- **mesothelioma incidence pattern**: we have tested the impact of shifting out the pattern of incidence by two further years.
There are other factors which influence the liability assessment and which could be sensitivity tested, including:

- The cross-claim recovery rate;
- The variation in timing of claim notifications (but with no change in the overall number of notifications); and
- The pattern and delay of claim settlements from claim notification.

We have not sensitivity tested these factors, viewing them as being of less financial significance individually.

We have not sensitivity tested the value of Insurance Recoveries as uncertainties typically relate to legal risk and disputation risk, and it is not possible to parameterise a sensitivity test in an informed manner.

We have not included a sensitivity test for the impact of changes in discount rates although, as noted in this Report, changes in discount rates can introduce significant volatility to the Discounted Central Estimate result reported at each year-end.

### 11.3 Results of sensitivity testing

The chart below shows the impact of various individual sensitivity tests on the Discounted Central Estimate of the liabilities, and of a combined sensitivity test of a number of factors.

Although we have tested multiple scenarios of each assumption, one cannot gauge an overall potential range by simply adding these tests together. Accordingly, we have prepared a range based on a combination of factors.

**Figure 11.1: Sensitivity testing results – Impact around the Discounted Central Estimate (in $m)**
The single most sensitive assumption shown in the chart is the incidence pattern of mesothelioma claims reporting against the Liable Entities. Shifting the pattern of incidence by 2 years could add approximately $325m (18%) on a discounted basis to our valuation (as shown in Figure 11.1 by the scenario labelled “mesothelioma incidence pattern”).

Table 11.1: Summary results of sensitivity analysis ($m)

<table>
<thead>
<tr>
<th></th>
<th>Undiscounted</th>
<th>Discounted</th>
</tr>
</thead>
<tbody>
<tr>
<td>Central estimate</td>
<td>2,380.9</td>
<td>1,852.9</td>
</tr>
<tr>
<td>Low Scenario</td>
<td>1,681.3</td>
<td>1,347.2</td>
</tr>
<tr>
<td>High Scenario</td>
<td>4,209.8</td>
<td>3,062.0</td>
</tr>
</tbody>
</table>

Whilst the table above indicates a range around the discounted central estimate of liabilities of -$506m to +$1,209m, the actual cost of liabilities could fall outside that range depending on the actual experience.

We further note that these sensitivity test ranges are not intended to correspond to a specified probability of sufficiency nor are they intended to indicate an upper bound or a lower bound of all possible outcomes.
<table>
<thead>
<tr>
<th>Payment Year</th>
<th>Mesothelioma Claims</th>
<th>Asbestososis Claims</th>
<th>Lung Cancer Claims</th>
<th>ARPD &amp; Other Claims</th>
<th>Other Claims</th>
<th>Workman Compensation Claims</th>
<th>Other Compensation Claims</th>
<th>Workoff Claims</th>
<th>Cross Claim Recoveries</th>
<th>Gross Claims</th>
<th>Net Claims</th>
<th>Burglary</th>
<th>Fire Claims</th>
<th>Other Claims</th>
<th>Incurred Claims</th>
</tr>
</thead>
</table>
### Projected Inflated and Discounted Cashflows ($m)

<table>
<thead>
<tr>
<th>Year/Quarters</th>
<th>Asbestos TimeUnit Claims</th>
<th>Asbestos Lung Cancer Claims</th>
<th>Asbestos Other Claims</th>
<th>ARPC &amp; Other Claims</th>
<th>Legal and Other Claims</th>
<th>Workers Compensation Claims</th>
<th>Workers Other Claims</th>
<th>Workers Legal and Other Claims</th>
<th>Other Claims</th>
<th>Workers Recovery</th>
<th>Workers Claim Recoveries</th>
<th>Cost Index</th>
</tr>
</thead>
<tbody>
<tr>
<td>2067/2068</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
</tr>
<tr>
<td>2068/2069</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
</tr>
<tr>
<td>2069/2070</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
</tr>
<tr>
<td>2070/2071</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
</tr>
<tr>
<td>2071/2072</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
</tr>
</tbody>
</table>

**Total:**

- **Inflated Total:** $1,632.4
- **Discounted Total:** $102.8
- **Net Cash Flows (Inflated):** $29.3
- **Net Cash Flows (Discounted):** $171.5
- **Net Cash Flows (Discounted):** $1.0
- **Cost:** $8.3
- **Profit:** $11.7
- **Profit:** $1.7
- **Profit:** $45.2
- **Profit:** $1,938.2
- **Profit:** $85.4
- **Profit:** $1,852.9
C  Australian asbestos consumption and production data: 1930-2002

Figures in this table are in 000's metric tonnes

<table>
<thead>
<tr>
<th>Year</th>
<th>Production</th>
<th>Import</th>
<th>Export</th>
<th>Consumption</th>
</tr>
</thead>
<tbody>
<tr>
<td>1930</td>
<td>130</td>
<td>1,200</td>
<td>-</td>
<td>1,328</td>
</tr>
<tr>
<td>1931</td>
<td>120</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>1932</td>
<td>742</td>
<td>-</td>
<td>-</td>
<td>742</td>
</tr>
<tr>
<td>1933</td>
<td>271</td>
<td>-</td>
<td>-</td>
<td>271</td>
</tr>
<tr>
<td>1934</td>
<td>217</td>
<td>-</td>
<td>-</td>
<td>217</td>
</tr>
<tr>
<td>1935</td>
<td>1,790</td>
<td>-</td>
<td>-</td>
<td>1,790</td>
</tr>
<tr>
<td>1936</td>
<td>3,034</td>
<td>-</td>
<td>-</td>
<td>3,034</td>
</tr>
<tr>
<td>1937</td>
<td>3,679</td>
<td>-</td>
<td>-</td>
<td>3,679</td>
</tr>
<tr>
<td>1938</td>
<td>255</td>
<td>3,934</td>
<td>-</td>
<td>3,934</td>
</tr>
<tr>
<td>1939</td>
<td>255</td>
<td>3,679</td>
<td>-</td>
<td>3,934</td>
</tr>
<tr>
<td>1940</td>
<td>217</td>
<td>-</td>
<td>-</td>
<td>217</td>
</tr>
<tr>
<td>1941</td>
<td>217</td>
<td>-</td>
<td>-</td>
<td>217</td>
</tr>
<tr>
<td>1942</td>
<td>217</td>
<td>-</td>
<td>-</td>
<td>217</td>
</tr>
<tr>
<td>1943</td>
<td>217</td>
<td>-</td>
<td>-</td>
<td>217</td>
</tr>
<tr>
<td>1944</td>
<td>217</td>
<td>-</td>
<td>-</td>
<td>217</td>
</tr>
<tr>
<td>1945</td>
<td>217</td>
<td>-</td>
<td>-</td>
<td>217</td>
</tr>
<tr>
<td>1946</td>
<td>217</td>
<td>-</td>
<td>-</td>
<td>217</td>
</tr>
<tr>
<td>1947</td>
<td>217</td>
<td>-</td>
<td>-</td>
<td>217</td>
</tr>
<tr>
<td>1948</td>
<td>217</td>
<td>-</td>
<td>-</td>
<td>217</td>
</tr>
<tr>
<td>1949</td>
<td>217</td>
<td>-</td>
<td>-</td>
<td>217</td>
</tr>
<tr>
<td>1950</td>
<td>217</td>
<td>-</td>
<td>-</td>
<td>217</td>
</tr>
<tr>
<td>1951</td>
<td>217</td>
<td>-</td>
<td>-</td>
<td>217</td>
</tr>
<tr>
<td>1952</td>
<td>217</td>
<td>-</td>
<td>-</td>
<td>217</td>
</tr>
<tr>
<td>1953</td>
<td>217</td>
<td>-</td>
<td>-</td>
<td>217</td>
</tr>
<tr>
<td>1954</td>
<td>217</td>
<td>-</td>
<td>-</td>
<td>217</td>
</tr>
<tr>
<td>1955</td>
<td>217</td>
<td>-</td>
<td>-</td>
<td>217</td>
</tr>
<tr>
<td>1956</td>
<td>217</td>
<td>-</td>
<td>-</td>
<td>217</td>
</tr>
<tr>
<td>1957</td>
<td>217</td>
<td>-</td>
<td>-</td>
<td>217</td>
</tr>
<tr>
<td>1958</td>
<td>217</td>
<td>-</td>
<td>-</td>
<td>217</td>
</tr>
<tr>
<td>1959</td>
<td>217</td>
<td>-</td>
<td>-</td>
<td>217</td>
</tr>
<tr>
<td>1960</td>
<td>217</td>
<td>-</td>
<td>-</td>
<td>217</td>
</tr>
<tr>
<td>1961</td>
<td>217</td>
<td>-</td>
<td>-</td>
<td>217</td>
</tr>
<tr>
<td>1962</td>
<td>217</td>
<td>-</td>
<td>-</td>
<td>217</td>
</tr>
<tr>
<td>1963</td>
<td>217</td>
<td>-</td>
<td>-</td>
<td>217</td>
</tr>
<tr>
<td>1964</td>
<td>217</td>
<td>-</td>
<td>-</td>
<td>217</td>
</tr>
<tr>
<td>1965</td>
<td>217</td>
<td>-</td>
<td>-</td>
<td>217</td>
</tr>
<tr>
<td>1966</td>
<td>217</td>
<td>-</td>
<td>-</td>
<td>217</td>
</tr>
<tr>
<td>1967</td>
<td>217</td>
<td>-</td>
<td>-</td>
<td>217</td>
</tr>
<tr>
<td>1968</td>
<td>217</td>
<td>-</td>
<td>-</td>
<td>217</td>
</tr>
<tr>
<td>1969</td>
<td>217</td>
<td>-</td>
<td>-</td>
<td>217</td>
</tr>
<tr>
<td>1970</td>
<td>217</td>
<td>-</td>
<td>-</td>
<td>217</td>
</tr>
<tr>
<td>1971</td>
<td>217</td>
<td>-</td>
<td>-</td>
<td>217</td>
</tr>
<tr>
<td>1972</td>
<td>217</td>
<td>-</td>
<td>-</td>
<td>217</td>
</tr>
<tr>
<td>1973</td>
<td>217</td>
<td>-</td>
<td>-</td>
<td>217</td>
</tr>
<tr>
<td>1974</td>
<td>217</td>
<td>-</td>
<td>-</td>
<td>217</td>
</tr>
<tr>
<td>1975</td>
<td>217</td>
<td>-</td>
<td>-</td>
<td>217</td>
</tr>
<tr>
<td>1976</td>
<td>217</td>
<td>-</td>
<td>-</td>
<td>217</td>
</tr>
<tr>
<td>1977</td>
<td>217</td>
<td>-</td>
<td>-</td>
<td>217</td>
</tr>
<tr>
<td>1978</td>
<td>217</td>
<td>-</td>
<td>-</td>
<td>217</td>
</tr>
<tr>
<td>1979</td>
<td>217</td>
<td>-</td>
<td>-</td>
<td>217</td>
</tr>
<tr>
<td>1980</td>
<td>217</td>
<td>-</td>
<td>-</td>
<td>217</td>
</tr>
<tr>
<td>1981</td>
<td>217</td>
<td>-</td>
<td>-</td>
<td>217</td>
</tr>
<tr>
<td>1982</td>
<td>217</td>
<td>-</td>
<td>-</td>
<td>217</td>
</tr>
<tr>
<td>1983</td>
<td>217</td>
<td>-</td>
<td>-</td>
<td>217</td>
</tr>
<tr>
<td>1984</td>
<td>217</td>
<td>-</td>
<td>-</td>
<td>217</td>
</tr>
<tr>
<td>1985</td>
<td>217</td>
<td>-</td>
<td>-</td>
<td>217</td>
</tr>
<tr>
<td>1986</td>
<td>217</td>
<td>-</td>
<td>-</td>
<td>217</td>
</tr>
<tr>
<td>1987</td>
<td>217</td>
<td>-</td>
<td>-</td>
<td>217</td>
</tr>
<tr>
<td>1988</td>
<td>217</td>
<td>-</td>
<td>-</td>
<td>217</td>
</tr>
<tr>
<td>1989</td>
<td>217</td>
<td>-</td>
<td>-</td>
<td>217</td>
</tr>
<tr>
<td>1990</td>
<td>217</td>
<td>-</td>
<td>-</td>
<td>217</td>
</tr>
<tr>
<td>1991</td>
<td>217</td>
<td>-</td>
<td>-</td>
<td>217</td>
</tr>
<tr>
<td>1992</td>
<td>217</td>
<td>-</td>
<td>-</td>
<td>217</td>
</tr>
<tr>
<td>1993</td>
<td>217</td>
<td>-</td>
<td>-</td>
<td>217</td>
</tr>
<tr>
<td>1994</td>
<td>217</td>
<td>-</td>
<td>-</td>
<td>217</td>
</tr>
<tr>
<td>1995</td>
<td>217</td>
<td>-</td>
<td>-</td>
<td>217</td>
</tr>
<tr>
<td>1996</td>
<td>217</td>
<td>-</td>
<td>-</td>
<td>217</td>
</tr>
<tr>
<td>1997</td>
<td>217</td>
<td>-</td>
<td>-</td>
<td>217</td>
</tr>
<tr>
<td>1998</td>
<td>217</td>
<td>-</td>
<td>-</td>
<td>217</td>
</tr>
<tr>
<td>1999</td>
<td>217</td>
<td>-</td>
<td>-</td>
<td>217</td>
</tr>
<tr>
<td>2000</td>
<td>217</td>
<td>-</td>
<td>-</td>
<td>217</td>
</tr>
<tr>
<td>2001</td>
<td>217</td>
<td>-</td>
<td>-</td>
<td>217</td>
</tr>
<tr>
<td>2002</td>
<td>217</td>
<td>-</td>
<td>-</td>
<td>217</td>
</tr>
</tbody>
</table>
D  Glossary of terms used in the Amended Final Funding Agreement

The following provides a glossary of terms which are referenced in the Amended Final Funding Agreement and upon which we have relied in preparing our report.

The operation of these definitions cannot be considered in isolation but instead need to be considered in the context of the totality of the Amended Final Funding Agreement.

AICF means the trustee of the Asbestos Injuries Compensation Fund from time to time, in its capacity as trustee, initially being Asbestos Injuries Compensation Fund Limited.

These terms also need to be read in conjunction with the Deed of Amendment dated 19 December 2017 which added a new clause (13.4A) and which is effective from 1 January 2018.

**AICF Funded Liability** means:

(a) any Proven Claim;
(b) Operating Expenses;
(c) Claims Legal Costs;
(d) any claim that was made or brought in legal proceedings against a Former James Hardie Company commenced before 1 December 2005;
(e) Statutory Recoveries within the meaning and subject to the limits set out in the Amended Final Funding Agreement;
(f) a claim or category of claim which James Hardie and the NSW Government agree in writing is a “AICF Funded Liability” or a category of “AICF Funded Liability”.

but in the cases of paragraphs (a), (c) and (d) excludes any such liabilities or claims to the extent that they have been recovered or are recoverable under a Worker’s Compensation Scheme or Policy.

**Claims Legal Costs** means all costs, charges, expenses and outgoings incurred or expected to be borne by AICF or the Former James Hardie Companies, in respect of legal advisors, other advisors, experts, court proceedings and other dispute resolution methods in connection with Personal Asbestos Claims and Marlew Claims but in all cases excluding any costs included as a component of calculating a Proven Claim.
**Concurrent Wrongdoer** in relation to a personal injury or death claim for damages under common law or other law (excluding any law introduced or imposed in breach of the restrictions on adverse regulatory or legislative action against the James Hardie Group under the Amended Final Funding Agreement, and which breach has been notified to the NSW Government in accordance with Amended Final Funding Agreement), means a person whose acts or omissions, together with the acts or omissions of one or more Former James Hardie Companies or Marlew or any member of the James Hardie Group (whether or not together with any other persons) caused, independently of each other or jointly, the damage or loss to another person that is the subject of that claim.

**Contribution Claim** means a cross-claim or other claim under common law or other law (excluding any law introduced or imposed in breach of the restrictions on adverse regulatory or legislative action against the James Hardie Group under the Amended Final Funding Agreement, and which breach has been notified to the NSW Government in accordance with Amended Final Funding Agreement):

(a) for contribution by a Concurrent Wrongdoer against a Former James Hardie Company or a member of the James Hardie Group in relation to facts or circumstances which give rise to a right of a person to make a Personal Asbestos Claim or a Marlew Claim; or

(b) by another person who is entitled under common law (including by way of contract) to be subrogated to such a first mentioned cross-claim or other claim;

**Discounted Central Estimate** means the central estimate of the present value (determined using the discount rate used within the relevant actuarial report) of the liabilities of the Former James Hardie Companies and Marlew in respect of expected Proven Claims and Claims Legal Costs, calculated in accordance with the Amended Final Funding Agreement.

**Excluded Claims** are any of the following liabilities of the Former James Hardie Companies:

(i) personal injury or death claims arising from exposure to Asbestos outside Australia;

(ii) personal injury or death claims arising from exposure to Asbestos made outside Australia;

(iii) claims for economic loss (other than any economic loss forming part of the calculation of an award of damages for personal injury or death) or loss of property, including those relating to land remediation and/or Asbestos or Asbestos products removal, arising out of or in connection with Asbestos or Asbestos products manufactured, sold, distributed or used by or on behalf of the Liable Entities;

(iv) any Excluded Marlew Claim;

(v) any liabilities of the Liable Entities other than AICF Funded Liabilities.

**Excluded Marlew Claim** means a Marlew Claim:

(a) covered by the indemnities granted by the Minister of Mineral Resources under the deed between the Minister, Fuller Earthmoving Pty Limited and James Hardie Industries Limited dated 11 March 1996; or

(b) by a current or former employee of Marlew in relation to an exposure to Asbestos in the course of such employment to the extent:

(i) the loss is recoverable under a Worker’s Compensation Scheme or Policy; or
the Claimant is not unable to recover damages from a Marlew Joint Tortfeasor in accordance with the Marlew Legislation;

c) by an individual who was or is an employee of a person other than Marlew arising from exposure to Asbestos in the course of such employment by that other person where such loss is recoverable from that person or under a Worker’s Compensation Scheme or Policy; or

d) in which another defendant (or its insurer) is a Marlew Joint Tortfeasor from whom the plaintiff is entitled to recover compensation in proceedings in the Dust Diseases Tribunal, and the Claimant is not unable to recover damages from that Marlew Joint Tortfeasor in accordance with the Marlew Legislation.

Former James Hardie Companies means Amaca, Amaba and ABN 60.

Insurance and Other Recoveries means any proceeds which may reasonably be expected to be recovered or recoverable for the account of a Former James Hardie Company or to result in the satisfaction (in whole or part) of a liability of a Former James Hardie Company (of any nature) to a third party, under any product liability insurance policy or public liability insurance policy or commutation of such policy or under any other contract, including any contract of indemnity, but excluding any such amount recovered or recoverable under a Worker’s Compensation Scheme or Policy.

Liable Entities see Former James Hardie Companies.

Marlew means Marlew Mining Pty Ltd (in liquidation), ACN 000 049 650, previously known as Asbestos Mines Pty Ltd.

Marlew Claim means, subject to the limitation on Statutory Recoveries, a claim which satisfies one of the following paragraphs and which is not an Excluded Marlew Claim:

(a) any present or future personal injury or death claim by an individual or the legal personal representative of an individual, for damages under common law or other law (excluding any law introduced or imposed in breach of the restrictions on adverse regulatory or legislative action against the James Hardie Group under the Amended Final Funding Agreement, and which breach has been notified to the NSW Government in accordance with the Amended Final Funding Agreement) which:

(i) arose or arises from exposure to Asbestos in the Baryulgil region from Asbestos Mining Activities at Baryulgil conducted by Marlew, provided that:

A. the individual’s exposure to Asbestos occurred wholly within Australia;

or

B. where the individual has been exposed to Asbestos both within and outside Australia, the amount of damages included in the Marlew Claim shall be limited to the amount attributable to the proportion of the exposure which caused or contributed to the loss or damage giving rise to the Marlew Claim which occurred in Australia;

(ii) is commenced in New South Wales in the Dust Diseases Tribunal; and
(iii) is or could have been made against Marlew had Marlew not been in external administration or wound up, or could be made against Marlew on the assumption (other than as contemplated under the Marlew legislation) that Marlew will not be in the future in external administration;

(b) any claim made under compensation to relatives legislation by a relative of a deceased individual (or personal representative of such a relative) or (where permitted by law) the legal personal representative of a deceased individual in each case where the individual, but for such individual’s death, would have been entitled to bring a claim of the kind described in paragraph (a); or

(c) a Contribution Claim relating to a claim described in paragraphs (a) or (b).

**Marlew Joint Tortfeasor** means any person who is or would be jointly and severally liable with Marlew in respect of a Marlew Claim, had Marlew not been in external administration or wound up, or on the assumption that Marlew will not in the future be, in external administration or wound up other than as contemplated under the Marlew Legislation.

**Payable Liability** means any of the following:

(a) any Proven Claim (whether arising before or after the date of this deed);

(b) Operating Expenses;

(c) Claims Legal Costs;

(d) any liability of a Former James Hardie Company to the AICFL, however arising, in respect of any amounts paid by the AICFL in respect of any liability or otherwise on behalf of the Former James Hardie Company;

(e) any claim that was made or brought in legal proceedings against a Former James Hardie Company commenced before 1 December 2005;

(f) if regulations are made pursuant to section 30 of the Transaction Legislation and if and to the extent the AICFL and James Hardie have notified the NSW Government that any such liability is to be included in the scope of Payable Liability, any liability of a Former James Hardie Company to pay amounts received by it from an insurer in respect of a liability to a third party incurred by it for which it is or was insured under a contract of insurance entered into before 2 December 2005; and

(g) Statutory Recoveries within the meaning and subject to the limits set out in the Amended Final Funding Agreement,

but in the cases of paragraphs (a), (c) and (e) excludes any such liabilities or claims to the extent that they have been recovered or are recoverable under a Worker’s Compensation Scheme or Policy.

**Period Actuarial Estimate** means, in respect of a period, the central estimate of the present value (determined using the discount rate used in the relevant actuarial report) of the liabilities of the Former James Hardie Companies and Marlew in respect of expected Proven Claims and Claims Legal Costs (in each case which are reasonably expected to become payable in that period), before allowing for Insurance and Other Recoveries, calculated in accordance with the Amended Final Funding Agreement.
**Personal Asbestos Claim** means any present or future personal injury or death claim by an individual or the legal personal representative of an individual, for damages under common law or under other law (excluding any law introduced or imposed in breach of the restrictions on adverse regulatory or legislative action against the James Hardie Group under the Amended Final Funding Agreement, and which breach has been notified to the NSW Government under the Amended Final Funding Agreement) which:

(a) arises from exposure to Asbestos occurring in Australia, provided that:
   (i) the individual’s exposure to Asbestos occurred wholly within Australia; or
   (ii) where the individual has been exposed to Asbestos both within and outside Australia, damages included in the Marlew Claim shall be limited to the amount attributable to the proportion of the exposure which caused or contributed to the loss or damage giving rise to the Personal Asbestos Claim which occurred in Australia;

(b) is made in proceedings in an Australian court or tribunal; and

(c) is made against:
   (i) all or any of the Liable Entities; or
   (ii) any member of the James Hardie Group from time to time;

(d) any claim made under compensation to relatives legislation by a relative of a deceased individual (or personal representative of such a relative) or (where permitted by law) the legal personal representative of a deceased individual in each case where the individual, but for such individual’s death, would have been entitled to bring a claim of the kind described in paragraph (a); or

(e) a Contribution Claim made in relation to a claim described in paragraph (a) or (b)

but excludes all claims covered by a Worker’s Compensation Scheme or Policy.

**Proven Claim** means a proven Personal Asbestos Claim in respect of which final judgment has been given against, or a binding settlement has been entered into by, a Former James Hardie Company, to the extent to which that entity incurs liability under that judgment or settlement, or a Proven Marlew Claim.

**Statutory Recoveries** means any statutory entitlement of the NSW Government or any Other Government or any governmental agency or authority of any such government (“Relevant Body”) to impose liability on or to recover an amount or amounts from any person in respect of any payments made or to be made or benefits provided by a Relevant Body in respect of claims (other than as a defendant or in settlement of any claim, including a cross-claim or claim for contribution).

**Term** means the period

(i) from the date on which the principal obligations under the Amended Final Funding Agreement will commence to 31 March 2045,

(ii) as may be extended in accordance with the terms of the Amended Final Funding Agreement.
**Term Central Estimate** means the central estimate of the present value (determined using the discount rate used in the relevant Annual Actuarial Report) of the liabilities of the Former James Hardie Companies and Marlew in respect of expected Proven Claims and Claims Legal Costs (in each case reasonably expected to become payable in the relevant period) after allowing for Insurance and Other Recoveries during that period, from and including the day following the end of the Financial Year preceding that Payment Date up to and including the last day of the Term (excluding any automatic or potential extension of the Term, unless or until the Term has been extended).

**Workers Compensation Scheme or Policy** means any of the following:

(a) any worker’s compensation scheme established by any law of the Commonwealth or of any State or Territory;

(b) any fund established to cover liabilities under insurance policies upon the actual or prospective insolvency of the insurer (including without limitation the Insurer Guarantee Fund established under the Worker’s Compensation Act 1987 (NSW)); and

(c) any policy of insurance issued under or pursuant to such a scheme.